Investigation on the Synthesis of *Shigella flexneri* Specific Oligosaccharides Using Disaccharides as Potential Transglucosylase Acceptor Substrates

Stéphane Salamone,^{†,‡,#} Catherine Guerreiro,^{†,‡} Emmanuelle Cambon,^{§,||,⊥} Jason M. Hargreaves,^{†,‡} Nathalie Tarrat,^{§,||,⊥} Magali Remaud-Siméon,^{§,||,⊥} Isabelle André,^{§,||,⊥} and Laurence A. Mulard^{*,†,‡}

[†]Institut Pasteur, Unité de Chimie des Biomolécules, 28 rue du Dr Roux, 75724, Paris Cedex 15 France

[‡]CNRS UMR 3523, Institut Pasteur, 75015 Paris, France


[§]Université de Toulouse, INSA,UPS,INP; LISBP, 135 Avenue de Rangueil, 31077 Toulouse, France

^{II}CNRS, UMR5504, F-31400 Toulouse, France

¹INRA, UMR792 Ingénierie des Systèmes Biologiques et des Procédés, F-31400 Toulouse, France

S Supporting Information

ABSTRACT: Chemo-enzymatic strategies hold great potential for the development of stereo- and regioselective syntheses of structurally defined bioactive oligosaccharides. Herein, we illustrate the potential of the appropriate combination of a planned chemo-enzymatic pathway and an engineered biocatalyst for the multistep synthesis of an important decasaccharide for vaccine development. We report the stepwise investigation, which led to an efficient chemical conversion of allyl α -D-glucopyranosyl- $(1\rightarrow 4)$ - α -L-rhamnopyranosyl- $(1\rightarrow 3)$ -2-deoxy-2-trichloroacetamido- β -D-glucopyranoside, the product of site-specific enzymatic α -D-glucosylation of a lightly protected non-natural disaccharide acceptor, into a pentasaccharide building block suitable for chain elongation at



both ends. Successful differentiation between hydroxyl groups features the selective acylation of primary alcohols and acetalation of a *cis*-vicinal diol, followed by a controlled per-O-benzylation step. Moreover, we describe the successful use of the pentasaccharide intermediate in the [5 + 5] synthesis of an aminoethyl aglycon-equipped decasaccharide, corresponding to a dimer of the basic repeating unit from the O-specific polysaccharide of *Shigella flexneri* 2a, a major cause of bacillary dysentery. Four analogues of the disaccharide acceptor were synthesized and evaluated to reach a larger repertoire of O-glucosylation patterns encountered among *S. flexneri* type-specific polysaccharides. New insights on the potential and limitations of planned chemo-enzymatic pathways in oligosaccharide synthesis are provided.

INTRODUCTION

The chemical assembly of complex oligosaccharides has progressed tremendously over the past decades.¹⁻⁵ Elegant chemical synthetic methods including modular solution-phase approaches⁶ or automated stepwise solid-phase syntheses⁷ of oligosaccharides encompassing more than 20 residues have been reported. Nevertheless, in the absence of general rules governing synthetic carbohydrate chemistry, the development of stereoselective syntheses of structurally defined oligosaccharides remains a challenging task. Complexity is increased owing to the impressive structural diversity of naturally occurring carbohydrates and, therefore, of synthetic targets. This is especially relevant in the case of glycans of microbial origin,⁸ in which interest is growing. Efficient protecting group manipulation toward tailored-made building blocks on the one hand and their stereoselective chemical assembly on the other hand remain major issues, particularly with regard to the

development of scalable synthetic processes or when multiple targets are involved. In some instances, enzymes have successfully emerged to circumvent these issues. Advantageously, synthesis using glycosyltransferases proceeds selectively in the absence of protecting groups,⁹ while some glycosidases could be converted into efficient glycosynthases¹⁰ or transglycosidases.¹¹ Evidently, access to naturally occurring carbohydrate-active enzymes is expanding, and in recent years, enzymatic syntheses and, as an extension, chemo-enzymatic pathways, have gained increasing attention owing to their powerful versatility in addition to high regio- and stereoselectivity.^{3,4,12–14} Purposely tailored biocatalysts could help bypass specific limitations encountered with chemical glycosylation; we therefore chose to explore a chemo-enzymatic

Received: June 21, 2015 Published: September 4, 2015 route in the context of *Shigella flexneri*, a family of Gramnegative enteroinvasive bacteria and one of the causes of shigellosis, otherwise known as bacillary dysentery, in humans.

With an estimated 122800 shigellosis-related deaths in 2010,¹⁵ shigellosis is one of the diarrheal diseases causing the most burden worldwide, especially among children living in developing countries.¹⁶ Rehydration is inadequate, and resistance to antibiotics is increasing.¹⁷ Above all, the renewed awareness of the burden of shigellosis in the pediatric population has encouraged the search for novel vaccine strategies aimed at broad Shigella species and type coverage. As an alternative to important developments involving the detoxified lipopolysaccharide and/or analogues purified from biological sources,¹⁸ we and others chose to investigate the impact of synthetic carbohydrates as active vaccine components.¹⁹⁻²¹ Thus, synthetic oligosaccharides representing functional mimics of the O-specific polysaccharide moiety (O-SP) of the bacterial membrane-anchored lipopolysaccharides are meant to replace the natural antigens.²² The efficient synthesis of tailored fragments of the Shigella O-SPs of interest is a prerequisite to the identification of oligosaccharides suitable for entering vaccine design and optimization.

S. flexneri encompasses a large diversity of types and subtypes which have been identified on the basis of the structure of their O-SPs. At least 15 of the identified O-SP repeating units share the same linear tetrasaccharide backbone, which is made of three L-rhamnose residues (A, B, C) and an N-acetyl-D-glucosamine residue (D), 1,2-trans-linked to one another. Type specificity is associated with the phage-encoded site-selective modification of the ABCD unit with α -D-glucopyranosyl residues (E), O-acetyl groups (Ac), and the more recently disclosed phosphoethanolamine residues (PEtN) (Figure 1).^{23,24}




Figure 1. *S. flexneri* O-SP backbone (ABCD) showing type/group-specific substitution and sites of α -D-glucosyl (E) appendage (in blue).

 α -D-Glucosylation can occur at any residue. It is always stoichiometric and is an essential feature of the most prevalent *S. flexneri* serotypes sharing the {ABCD}_n backbone.^{23,25} Concern for these important glucosyl side chains has been addressed repeatedly in the published chemical syntheses of *S. flexneri* oligosaccharides, most of which used readily available tetrabenzylglucosyl donors.^{26–31} However, the 1,2-*cis* α -linkage has precluded stereospecific glucosylation, and α/β mixtures were isolated despite parameter optimization. Evolution from tetrabenzyl donors to those more diversely protected at remote positions such as analogues equipped with ester protecting groups at O-6³² and conformationally constrained precursors^{33–35} has been shown to enhance α/β ratios. Alternatively, prearranged donor/acceptor systems for intramolecular aglycon delivery,^{36,37} mannose-to-glucose sequential oxidation-reduction,³⁸ and precursors designed for hydrogen bond mediated aglycon delivery³⁹ have been employed successfully. Furthermore, impressive progress in the area of stereocontrolled chemical 1,2-cis glucosylation has been achieved as exemplified by sophisticated donors enabling neighboring group participation by means of a C-2 (S)-auxiliary⁴⁰ or prepared in the form of precyclized 1,2-oxathiane precursors.⁴¹⁻⁴³ Nevertheless, despite remarkable realizations, concerns emerged due to increasing donor complexity and/or potential interferences with protecting group selection, branching patterns, subsequent chain elongation, substituent manipulation, or final deprotection. For systems such as S. flexneri, for which diversely substituted O-SPs and fragments thereof are identified as synthetic targets, these inherent drawbacks have to be evaluated on a case-to-case basis. Instead, we chose to investigate the input of enzymatic glucosylation.

Shigella type-specific O-SP glucosylation takes place on the periplasmic side of the cytoplasmic membrane on the growing membrane-anchored O-SP chain. Glucosylation involves serotype-specific glucosyltransferases featuring several transmembrane domains and a common membrane-anchored undecaprenyl-phosphate- β -glucose donor.⁴⁴ With this in mind, we chose to investigate novel chemo-enzymatic routes to diverse α -D-glucosylated oligosaccharides by use of sucroseutilizing transglucosylases. Otherwise known as glucansucrases, the selected biocatalysts are α -retaining enzymes found in glycoside-hydrolase families 13 (GH13) and 70 (GH70) of the CAZy classification.⁴⁵ Owing to a remarkable plasticity, they have evolved into biocatalysts with novel substrate specificities.⁴⁶ Moreover, relying on computer-aided engineering, we have identified mutants of the amylosucrase from Neisseria polysaccharea (NpAS), which catalyze the regiospecific α -Dglucosylation of two non-natural monosaccharides into motifs of interest in the context of S. flexneri.^{47,48} Featuring a related strategy, Armand et al. have shown that Bacillus circulans 251 cyclodextrin glucanotransferase (CGTase, EC 2.1.4.19) was able to accommodate non-natural rhamnoside acceptors and produce α -D-glucosylated products, identified as relevant building blocks for the synthesis of various S. flexneri O-SP fragments.49


As seen from our previous achievements,^{47,49} the strategy that we have undertaken aims at developing target-oriented synthetic routes encompassing an early-stage enzymatic step. Therefore, acceptor substrates are fine-tuned in order to access a variety of glucosylation profiles compatible with subsequent chemical elongation. Having established the concept of programmed chemoenzymatic pathways to microbial carbohydrates by use of purposely tailored glycoenzymes in the case of monosaccharide acceptors,^{47,49} our current effort aims at investigating the same approach in the case of non-natural disaccharide acceptors relevant to the design of a *S. flexneri* multivalent vaccine. The overall aim is to access oligosaccharides from several independent *S. flexneri* O-SPs starting from a single disaccharide, designed for use in acceptor reactions with properly engineered biocatalysts.

Obviously, the choice of the acceptor/transglucosylase system is a key issue governing the implementation of efficient tailored chemoenzymatic syntheses of complex glucosylated targets. Since the panel of known transglucosidases is highly diverse, acceptor selection controls the choice of the whole system. The acceptor has to fulfill several criteria, such as

relevance to epidemiological data and potential for broad serotype coverage. In addition, compatibility with the chemical manipulation of the product of enzymatic glucosylation into *S*. *flexneri* type-specific oligosaccharides is an absolute must. Among the four possible disaccharides found on the backbone shared by most *S*. *flexneri* O-SPs (Figure 1), the L-rhamnosyl- $(1\rightarrow 3)$ -2-*N*-acetyl-D-glucosamine moiety (CD) emerged as the one paving the way to the largest diversity of glucosylated products representative of any one of multiple *S*. *flexneri* serotypes.

To fulfill requirements for chemical chain elongation, the lightly protected CD analogue 1 was preferred to unprotected disaccharide CD as an acceptor substrate (Scheme 1).⁵⁰ Allyl glycoside 1 was shown to act as an acceptor substrate for several glucansucrases from the GH70 family,⁵⁰ including GBD-

Scheme 1. Enzymatic Glucosylation of Acceptor Substrate 1 into Trisaccharide 2 Catalyzed by the GH70 Glucansucrase Called GBD-CD2⁵⁰



CD2, an α -transglucosylase engineered from *Leuconostoc* mesenteroides NRRL B-1299 dextransucrase (DSR-E). In particular, as a rewarding illustration of this powerful concept, we have recently communicated⁵⁰ on the high-yielding GBD-CD2-mediated enzymatic glucosylation of the selected disaccharide 1 into trisaccharide 2, which features the α -D-Glcp-(1 \rightarrow 4)- α -L-Rhap glucosylation pattern characteristic for *S*. *flexneri* type II²³ (Scheme 1) and on the efficient conversion of the latter into a pentadecasaccharide hapten entering in the composition of a synthetic carbohydrate-based vaccine candidate against *S*. *flexneri* 2a (SF2a) infection.²¹

Herein, we report on the stepwise investigation which led to an efficient conversion of the glucosylation product 2 into a pentasaccharide building block 4, suitable for chain elongation at both ends (Scheme 2), as demonstrated in the synthesis of an aminoethyl aglycon-equipped dimer $(5)^{51}$ of the basic repeating unit from SF2a O-SP.²³

Moreover, we also report on the synthesis of analogues of the GBD-CD2 acceptor substrate 1, featuring a masked $4_{\rm C}$ -OH (6 and 7) or modified at the reducing end (8 and 9) (Figure 2) and on their evaluation as substrates of available glucansucrases differing in terms of substrate and regiospecificity.





Figure 2. Chemical structures of the CD disaccharide acceptor analogues modified at position $4_{\rm C}$ (6, 7) or $1_{\rm D}$ (8, 9).



Scheme 2. Highlights of the Synthesis of Decasaccharide 5 from the Product of Enzymatic Glucosylation 2, Showing the Key Protected Intermediates 3 and 4^{a}

^{*a*}The development of efficient $[2 \rightarrow 3]$, $[3 \rightarrow 4]$, and $[4 \rightarrow 5]$ transformations, respectively, corresponds to issues addressed independently in the manuscript.

RESULTS AND DISCUSSION


Having produced trisaccharide 2 in high yield from the easily accessible GBD-CD2 acceptor substrate 1,50 our first objective was to demonstrate that the former could be converted into either a donor or an acceptor for use in glycosylation reactions. Since the CD disaccharide 1 had been designed toward this aim, the ECD trisaccharide 2 fulfills primary requirements at its D residue. It features a temporary allyl protecting group at the reducing end and a 2_D-N-trichloroacetyl moiety to ensure efficient anchimeric assistance in the D-A glycosylation step along with recovery of the 2_D-acetamido moiety upon final deprotection. However, trisaccharide 2 also has eight free hydroxyl groups, of which two are primary alcohols. Therefore, careful protection/deprotection sequences were required to allow elongation at the reducing end and/or at OH-3 of the C residue of precursor 2 so as to reach more complex SF2a oligosaccharides.

Owing to the *cis* configuration of the $2_{C}3_{C}$ -diol moiety, the acetonide-protected 17 was seen as an ideal intermediate to the fully protected 3. The higher stability of 1,3-cis-dioxolanes over 1,3-dioxanes toward hydrolysis is a well-acknowledged phenomenon, which has been thoroughly exemplified.⁵ Following optimization of the reaction conditions, the expected chemoselectivity was obtained providing monoisopropylidene 12 in yields up to 89% using aqueous acetic acid at 0 °C for the selective hydrolysis of the 4,6-acetal in the EC disaccharide 11, itself derived from the known methyl glycoside 10⁵⁵ (Scheme 3A). Hence, trisaccharide 2 was submitted to a similar two-step process (Scheme 3B). Treatment of octaol 2 with excess 2methoxypropene in acetone under acidic catalysis ensured its conversion into a mixture of the expected triisopropylidene 13 and the fully protected 14, isolated in 49% and 39% yields, respectively. Acetalation of the $2_{E_2}3_E$ -diol under these kinetic conditions has been reported previously,⁵⁶ but it was not perceived to be problematic due to the high lability of the 1,2trans configuration. However, the selective deprotection of the isolated mixture of compounds 13 and 14 proved troublesome. Under mild hydrolysis conditions, ranging from conventional protic-mediated hydrolysis controlling, hanging from conventional protic-mediated hydrolysis, ^{57,58} which was efficient on the EC model **11**, to less common protocols such as the use of molecular iodine in acetonitrile⁵⁹ or that of silica gel supported phosphomolybdic acid,⁶⁰ the deprotection pattern was similar despite different kinetics. As expected, the 2_E,3_E-O-isopropylidene was rapidly cleaved to give the sole intermediate 13. Furthermore, the 6-membered $4_{E,6_E}$ -acetal was rather labile, providing access to tetraol 15 as unambiguously ascertained following isolation and per-acetylation into the fully protected 16. In contrast, the 1,3-dioxane masking the 4_D , 6_D -diol was comparably stable to the 1,3-cis-dioxolane blocking positions $2_{\rm C}$ and 3_{C} . Because of this unexpected observation, the reaction had to be monitored carefully in order to avoid complete deprotection. The I₂/MeCN conditions gave the best yield of monoacetonide 17 (76%) in only a few hours. However, in our hands, the reaction suffered from lack of reproducibility, with yields ranging from 37% to 76%, and a more robust pathway to the fully protected 3 was required.

Toward this goal, preliminary protection of the primary alcohols before installing the 2_{C} , 3_{C} -acetonide was investigated as an alternative. In order to extend the weight of the enzymatic input, regioselective *O*-acetylation by means of the well-known lipase B from *Candida antarctica* (CAL-B, also known as Novozym 435) in combination with vinyl acetate as donor was


Featured Article

Scheme 3. Synthesis of Monoacetonide 17: The Acetonide Route a



"Reagents and conditions: (A-a) 2,2-dimethoxypropane (DMP), cat. p-toluenesulfonic acid (p-TSA), DMF/acetone 1:1, 7.5 h, 86%, (A-b) 50% aq AcOH, 0 °C, 4.5 h, 89%; (B-a) 2-methoxypropene, cat. camphorsulfonic acid (CSA), acetone, 2 h, 49% for 13, 39% for 14; (B-b) cat. I₂, H₂O, MeCN, 2.75 h, 76%; (B-c) Ac₂O, cat. DMAP, Py, 2 h, 87%.






^aReagents and conditions: (a) vinyl acetate, CAL-B, THF/Py (4:1) 45 °C, 17 h, 88%.

first attempted.^{61–63} Once more, while the selective 6_D -*O*-acetylation of the CD disaccharide **1** proceeded in high yield (88%) to give monoacetate **18** (Scheme 4), adaptation to trisaccharide **2** was not as efficient. At best, 8% of the target 6_D , 6_E -diacetate, albeit contaminated, was obtained, along with a mixture of monoacetates and starting material (not shown). Since these attempts also clearly demonstrated that the two acetate esters did not sufficiently increase lipophilicity to allow proper isolation of the target trisaccharide, the enzymatic route was abandoned.

Instead, we turned our attention to the selective chemical installment of benzoate esters. Optimization of the reaction conditions enabled the development of a process that accommodated a good balance in the solubility of the starting material **2** and expected product **19** as well as a higher reactivity of primary hydroxyls over secondary ones. Thus, octaol **2** was treated with benzoyl chloride and a hindered nucleophilic

catalyst (sym-collidine) in a mixture of acetone/MeCN at -40 °C for 2 days to give dibenzoate 19 in a reproducible satisfactory 65% yield. The subsequent 2_{Cl}3_C-O-isopropylidenation of the latter into tetraol 20 (92%) and debenzoylation (94%) were uneventful and furnished monoacetonide 17 in high yield (Scheme 5). When masking the remaining hydroxyl groups of the latter as benzyl ethers while avoiding Nbenzylation, the reaction was carried out at -10 °C using only a slight excess of benzyl bromide.⁶⁴ Indeed, available data suggest that the trichloroacetamide moiety of amino sugars is prone to N-benzylation or even cleavage when treated according to various O-benzylation protocols.⁶⁴ Moreover, after the sodium hydride in excess was quenched by addition of MeOH, the resulting sodium methoxide was neutralized by addition of acetic acid to protect the base-labile trichloroacetamide during evaporation of the volatiles.⁶⁴ Under these conditions, the fully protected trisaccharide 3 was obtained in 78% yield.

Scheme 5. Synthesis of Monoacetonide 17 and Subsequent Benzylation: The Ester Route a




^aReagents and conditions: (a) BzCl, sym-collidine, MeCN/acetone (1:1), -40 °C, 46 h, 65%; (b) DMP, CSA, acetone, 2 h, 92%; (c) MeONa, MeOH, 3.3 h, 94%; (d) NaH, BnBr, DMF, -10 °C, 4 h, 78%.

Scheme 6. Synthesis of Pentasaccharide 24 by Use of Donor 22^a


In order to use the desired convergent [5 + 5] strategy to decasaccharide 5 (Scheme 1), conditions for a high-yielding glycosylation at the D-A linkage were required. Until recently, the investigation of convergent syntheses to SF2a oligosaccharides involving a disconnection at the D-A linkage was ruled out in our laboratory, essentially because of problems encountered by Bundle et al. in the synthesis of S. flexneri Y O-SP fragments.^{65,66} Instead, we favored a disconnection at the C–D linkage.^{51,67} However, the system described herein differs in many instances from the halide-equipped oligosaccharide donors bearing a 2_D-N-phthalimido participating group at their reducing end residue, which served in the S. flexneri Y studies.^{65,66} Hence, the next focus was on using ECD as a donor in a [3 + 2] glycosylation to prepare the model ECDAB pentasaccharide 24 (Scheme 6). To this end, trisaccharide 3 was submitted to a selective two-step anomeric deallylation involving conventional allyl to propen-1-yl conversion by means of the $[Ir(COD){PCH_3(C_6H_5)_2}]^+PF_6^-$ catalyst⁶⁸ and ⁹ giving rise to hemisubsequent iodine-mediated hydrolysis,⁶ acetal 21 (80%). The latter was in turn activated in the form of trichloroacetimidate 22 (70%, 93% corrected yield) by treatment with trichloroacetonitrile in the presence of a catalytic amount of DBU. Coupling of the known AB acceptor 23^{70} and donor 22 at low temperature in DCE containing 10 mol % of TMSOTf gave pentasaccharide 24 in a good 78% yield with complete β -selectivity.

Having demonstrated that the product of enzymatic glucosylation 2 could be converted into a potent donor, we turned our attention to the preparation of a fully protected AB(E)CD building block 4. First, cleavage of the isopropylidene acetal in trisaccharide 3 by use of a biphasic aqueous TFA/CH_2Cl_2 system revealed the corresponding $2_{C_2}3_{C_2}$ -diol 25 (94%) (Scheme 7). Next, the 2_{C} -hydroxyl group was benzoylated through orthoester formation followed by regioselective acid-mediated opening,²⁸ yielding acceptor **26** (82%). The known rhamnosyl trichloroacetimidate **28**,⁷¹ bearing a levulinyl ester orthogonal to the benzoyl group at position 2, was the selected donor. However, none of the [26 +**28**] glycosylation attempts, differing in terms of solvent (Et₂O, CH₂Cl₂, toluene) and temperature (-15 °C, 25 °C, 70 °C), led to any tetrasaccharide formation (not described). Alcohol 26 was recovered unaffected while donor 28 eventually rearranged into trichloroacetamide 29.72 The total absence of glycosylated product was not anticipated, especially since a 2_C-benzoyl ester had been used in the synthesis of SF2a oligosaccharides, albeit on different substrates, in our group in the past.^{51,67,73}



^aReagents and conditions: (a) cat. $[Ir(COD){PCH_3(C_6H_5)_2}]^PP_6^-([Ir])$, H₂, THF, 2.5 h, then I₂, THF/H₂O, 5 h, 80%; (b) CCl₃CN, cat. DBU, DCE, -10 °C, 35 min, 70%; (c) TMSOTf (10 mol %), DCE, -35 to 0 °C, 30 min, 78%. TCA: trichloroacetimidoyl.

Scheme 7. Synthesis of the B(E)CD Acceptor 33^{a}



^aReagents and conditions: (a) 50% aq TFA, CH₂Cl₂, 75 min, 94%; (b) PhC(OMe)₃, *p*-TSA, CH₂Cl₂, 20 min then 50% aq TFA, 45 min, 82%; (c) MeC(OMe)₃, *p*-TSA, MeCN, 35 min, then 80% aq AcOH, 0 °C, 25 min; (d) **28**, TMSOTf (5 mol %), Et₂O, -15 °C, 40 min, 81% from **25**, via **27**; (e) H₂NNH₂, Py/AcOH (3:2), 0 °C, 70 min, 92%.




Figure 3. Temperature dependence of δ (3_C-OH) measured by ¹H NMR (400 MHz) for 15 mM solutions of 26 (\blacklozenge) and 27 (\blacksquare) in DMSO-d₆.

Interestingly, we have previously pointed to the somewhat poor reactivity of the 2_D-acetamido-4_D,6_D-O-isopropylidene-ECD acceptor 30, which closely resembles trisaccharide 26, when treated with the known 2-O-acetyl rhamnosyl donor 31,74 analogous to 28. In spite of this observation and in contrast to the present finding, the target glycosylation product had been in this case obtained with moderate to good yield.⁷⁵ Whereas it was tempting to correlate the low reactivity of acceptor 30 with the known remote effect of the 2_D -acetamido moiety,⁷⁶ we had no explanation for the present outcome involving acceptor 26. Changing the $2_{\rm C}$ -benzoate in the latter for a $2_{\rm C}$ -acetate provided analogue 27, also obtained as a single product from diol 25 upon regioselective opening of an intermediate orthoester.⁵⁰ Satisfactorily, the [27 + 28] glycosylation proceeded smoothly to give tetrasaccharide 32 in a good 81% yield (from 25), thus confirming that ECD could also serve as an acceptor. Delevulinylation of the fully protected 32 by means of hydrazine acetate then led to the B(E)CD acceptor 33 (92%).⁵⁰ The striking difference in reactivity between the 2_C-O-benzoyl acceptor and its 2_C-O-acetyl counterpart, 26 and

27, respectively, was puzzling. We postulated that it could either be a consequence of a steric clash between the donor and acceptor 26, or of an intramolecular hydrogen bond established between the 3_C-OH and the ester carbonyl moiety that would only occur in the case of the benzoate from acceptor 26. It was hypothesized that if present, the latter phenomenon would either lower the electron density on the reactive hydroxyl group or constrain the molecule in a conformation less favorable for glycosylation. This hypothesis was addressed first by proper NMR analysis of the two hydroxy-esters in an aprotic solvent, which enables the detection of both intra- and intermolecular hydrogen bonds involving hydroxyl groups.⁷⁷ Measuring the ¹H NMR spectrum for each of the two samples in DMSO- d_6 solution at 10° intervals from 303 to 353 K clearly showed linear upfield shifts of the 3_C-OH, which were almost similar. The shift ranged between 0.002 and 0.008 ppm/°C, indicating that both hydroxyl groups were actually engaged in intramolecular hydrogen bonding (Figure 3).

In contrast, ab initio quantum chemical calculations of the two disaccharides shed light on their different conformational

Featured Article





Figure 4. Local energy minima conformations adopted by the 2_{C} -O-benzoyl acceptor 26 (a and b) and by the 2_{C} -O-acetyl acceptor 27 (c). For clarity, benzyl ethers are truncated and represented as magenta circles. Distances between atoms are given in angstroms.

Scheme 8. Synthesis of Tetrasaccharides B(E)CD 36 and 37^a



^aReagents and conditions: (a) 34, TMSOTf (9 mol %), toluene, 70 °C, 60 min, 20%, contaminated; (b) TMSOTf (5 mol %), toluene, -15 °C, 10 min, 80%.

behaviors. In the case of the 2_{C} -O-benzoyl trisaccharide 26, two local energy minima were found upon optimization using the DFT/B3LYP/6-31G(3df,3pd) level (Figure 4a,b and Tables S1 and S2, Supporting Information), corresponding to geometries that mainly differ in the orientation of the $3_{\rm C}$ -OH. In the first situation, the hydroxyl group is involved in a hydrogen-bonding interaction with the carbonyl of the vicinal ester, as hypothesized (Figure 4a). In the other minimal energy conformation, which is also more stable by $\Delta E = 4.8$ kcal/ mol, the 3_C-OH interacts with the endocyclic oxygen from the branched glucosyl residue E (Figure 4b). In contrast, the 2_C-Oacetyl trisaccharide 27 adopts a single energy minimum conformation, which closely resembles the more stable conformation in trisaccharide 26. Analogously, it is stabilized by a hydrogen bond between the 3_C-OH group and the endocyclic oxygen from residue E (Figure 4c and Table S3, Supporting Information). All attempts to localize an energy minimum in which the 3_C-OH was involved in a hydrogen bond with the acetate carbonyl moiety in trisaccharide 27 were fruitless as calculations repeatedly converged toward one single energy well. The calculated Mulliken charges on the 3_C-oxygen atom for the observed energy minima conformations are 0.76 and 0.85 (Figure 4a,b, respectively) for the benzoylated 26 and 0.86 for the acetylated 27, respectively. Since the $3_{\rm C}$ -OH of the

most stable conformations of the two hydroxy esters have similar charges, it could be assumed that the hydrogen bonding had no crucial influence on the electron density of the $3_{\rm C}$ -oxygen involved in the B–C linkage. However, the most stable conformation of the benzoylated **26** clearly showed steric hindrance at the $3_{\rm C}$ -OH brought by the aromatic ring of the vicinal benzoyl group, which could be held accountable for its lower reactivity.

With these new data in hand, the "steric hindrance" hypothesis was investigated more deeply by coupling acceptor 26 with the less hindered tri-O-acetyl rhamnosyl donor⁷⁵ 34 (Scheme 8). Despite the harsh conditions, a substantial amount of unreacted acceptor was recovered (70%), while most of the donor was hydrolyzed into the known hemiacetal⁸⁰ 35. Nevertheless, a new product was isolated, even though impure, which was tentatively identified as the coupling product 36, based on mass spectrometry analysis (HRMS (ESI⁺) calcd for $C_{84}H_{92}Cl_3NO_{23}Na [M + Na]^+$, 1610.5023, found m/z1610.5002). It is noteworthy that from this point forward some NMR signals from the A or B rhamnoses in the B(E)CDtetrasaccharides and larger oligosaccharides would either be broadened or absent. As another example, the coupling of donor 28 and the less hindered diol 25 unambiguously furnished the $2_{\rm C}$ -O-rhamnosyl tetrasaccharide 37 (Scheme 8).




Figure 5. Conformation of the local energy minimum of diol 25 highlighting steric hindrance around the 3_{C} -OH (view a) and accessibility of the 2_{C} -OH (view b). Distances between atoms are given in angstroms. The 2_{C} -OH group is encircled.

This outcome is in total agreement with data from Kong and Du, who found that glycosylation at the 3-OH of 2,3,4-triol rhamnoside acceptors is strongly favored, whereas in the case of 2,3-diol rhamnosides, glycosylation occurs preferentially at the axial 2-OH.⁸¹

Molecular modeling of diol 25 using the DFT/B3LYP/6-31G(3df,3pd) level indicated two energy minima corresponding to geometries that mainly differ in the orientation of the 3_C-OH. In the first minimal energy conformation (Table S4, Supporting Information), the hydroxyl group is involved in a hydrogen-bonding interaction with the 2_C-oxygen. In the other major conformation (Figure 5 and Table S5, Supporting Information), which is also more stable by 7 kcal/mol, the 3_{C} -OH interacts with the endocyclic oxygen of residue E as also observed for trisaccharides 26 and 27. The energy difference between these two conformers is such that only the lower local minimum is occupied. In the corresponding conformer, the charges on the oxygen atoms at positions 2_C and 3_C are similar, indicating that charge effects do not account for the observed regioselectivity. Rather, the latter is thought to arise from steric hindrance at the equatorial $3_{\rm C}$ oxygen atom (Figure 5a). Indeed, the 3_C-OH takes part in three hydrogen bonds. It is in close proximity of H-1_E and also interacts with the phenyl ring of the 6_E-benzyl ether. In comparison to this highly constrained situation, the $2_{\rm C}$ -OH group is easily accessible (Figure 5b, black circle).


We then moved on to the preparation of the [AB(E)CD], decasaccharide (Scheme 9). To this end, acceptor 33 was coupled with donor 28 allowing the formation of pentasaccharide 38 (86%). Deallylation of the latter gave hemiacetal 39 (93%), which was in turn converted to the key trichloroacetimidate 40 (97%). In order to equip the acceptor for siteselective conjugation, donor 40 was glycosylated with bromoethanol and the bromine atom was substituted with sodium azide to reach the fully protected azidoethyl glycoside 43 (78%). A delevulinylation step led to acceptor 44 (90%), which was then glycosylated with the same key donor 40. Although the reaction was run at 40 °C, very little condensation was detected. Instead, the donor rapidly evolved into the trichloro-oxazoline 45. Satisfactorily, subsequent addition of TMSOTf to reach 15 mol % allowed the full consumption of the acceptor. Yet, despite several attempts at purifying the fully

protected 46 by column chromatography using different elution systems, the latter could not be isolated as pure material. Indeed, a MALDI analysis clearly indicated that the decasaccharide was slightly contaminated with trichloroacetamide 42 (HRMS (ESI⁺) calculated for C₁₁₁H₁₂₀Cl₆N₂O₂₆Na $[M + Na]^+$ 2129.62, found *m*/*z* 2129.37), a rearranged form of donor 40. Attempts at purifying the decasaccharide at the next step were disappointing (not shown). For that reason, trichloroacetimidate 40 was changed for the corresponding N-phenyltrifluoroacetimidoyl (PTFA) donor 41,50 obtained in 83% yield from hemiacetal 39. Gratifyingly, the glycosylation between the new donor 41 and acceptor 44 performed at -10°C gave a good 82% yield of the desired decasaccharide 46. Methanolysis of the latter into triol 47 (72%) required unoptimized harsh conditions as previously experienced for a closely related decasaccharide.⁵¹ Treatment of triol 47 with $Pd(OH)_2/C$ under a hydrogen atmosphere enabled the concomitant benzyl ether hydrogenolysis, trichloroacetamide hydrodechlorination, and azide reduction to give, in 58% yield following RP-HPLC purification, the $[AB(E)CD]_2$ target 5, which corresponds to a two-unit segment of the S. flexneri 2a O-SP equipped with a linker enabling site-selective conjugation.

Capitalizing on the excellent outcome of the enzymatic regioselective α -D-glucosylation of the CD disaccharide 1 and the successful conversion of the obtained ECD 2 into relevant synthetic fragments of the O-SP from S. flexneri 2a as exemplified by decasaccharide 5, a functional mimic of the homologous O-SP,²² we questioned the potential of acceptor 1 as a precursor to α -D-glucosylation patterns characteristic of O-SPs from other S. flexneri serotypes (Figure 6). In particular, the α -D-glucosylation at O-4_D and O-6_D would open the way to oligosaccharides representative of O-SPs from S. flexneri type I and type IV, respectively.²³ In the following part of this article, we report on preliminary investigations toward this aim. To probe this hypothesis, minor modifications of the original acceptor 1 were considered, so as to identify any novel regioselectivity by use of GBD-CD2 and NpAS, a glucansucrase from GH13 family,⁸² in combination with sucrose as donor. The former naturally forms α -(1 \rightarrow 2) glucosidic bonds, whereas the latter catalyzes the α -(1 \rightarrow 4) linkage synthesis.

The most straightforward approach to a modified CD acceptor was to mask the $4_{\rm C}$ -OH in the starting allyl glycoside

Scheme 9. Synthesis of the Target Decasaccharide 5^d



^aReagents and conditions: (a) **28**, TMSOTf (7 mol %), Et₂O, -15 °C, 86%; (b) [Ir], H₂, THF, 2.5 h, then I₂, THF/H₂O (3:1), 4.5 h, 93%; (c) CCl₃CN, cat. DBU, DCE, -10 °C, 40 min, 97%; (d) CF₃C(NPh)Cl, Cs₂CO₃, acetone, rt, 2 h, 83%; (e) **40**, bromoethanol, TMSOTf (10 mol %), DCE, 0 °C, 25 min, then NaI, NaN₃, DMF, 80 °C, 2 h, 78%; (f) H₂NNH₂, AcOH/Py (2:3), 0 °C, 90%; (g) **41**, TMSOTf (20 mol %), toluene, -10 °C, 2 h, 82%; (h) MeONa, MeOH, 21 h, 71%; (i) H₂, Pd(OH)₂/C *t*-BuOH/CH₂Cl₂/H₂O, 3 d, 58%.





Figure 6. S. *flexneri* type-specific oligosaccharides in reach from CD following regioselective α -D-glucosylation at the positions indicated by the arrows.²³

1. To this end, two different targets were envisaged. The $4_{\rm C}$ -OH was blocked in the form of a methyl ether (6), and alternatively, it was oxidized into a $4_{\rm C}$ -oxo moiety, therefore also interfering with the ${}^{1}C_{4}$ ring conformation of L-rhamnose C, to give allyl glycoside 7 bearing conformational properties different from that of native 1 (Scheme 10). Toward this aim, di-O-isopropylidenation of disaccharide 1 gave the common intermediate 48 (75%), which underwent O-methylation with methyl iodide in THF⁸³ to give the fully protected 49 (89%). It


is noteworthy that performing the reaction in THF and using sodium hydride as the base was essential. Indeed, methylation attempts in DMF containing silver oxide or sodium hydride, or in THF containing silver oxide, resulted in partial *N*methylation of the trichloroacetamide moiety (not shown), as already observed by Scharf and Jütten in their synthesis of evernitrose.⁸⁴ This phenomenon is attributed to the strong inductive effect of the trichloroacetyl group, which enhances the acidity of the amide proton. The fully protected **49** was then submitted to acid-mediated acetal hydrolysis, leading to the expected 4_C-OMe disaccharide **6** (82%). Alternatively, alcohol **48** was oxidized using Swern conditions into ketone **50** (84%), which was then deacetalated into the 4_C-oxo derivative 7 (69%).


We attempted to force glucosylation of disaccharide CD at positions different from $4_{\rm C}$ -OH. To this end, acceptor reaction with disaccharides **6** and 7, both lacking a free $4_{\rm C}$ -OH, were performed with GBD-CD2. The LC-MS follow-up of the enzymatic conversion showed that no glucosylation product

Scheme 10. Synthesis of the CD Disaccharides 6 and 7, Encompassing a Masked 4_C-OH^a



^{*a*}Reagents and conditions: (a) 2-methoxypropene, DMP, cat. CSA, DMF/acetone 1:1, 36 h, 75%; (b) NaH, MeI, THF, 3 h, 89%; (c) 50% aq TFA, CH₂Cl₂, 35 min, 82%; (d) (COCl)₂, DMSO, Et₃N, CH₂Cl₂, -78 °C \rightarrow rt, 75 min, 84%; (e) 80% aq AcOH, 80 °C, 15 h, 69%.





^aReagents and conditions: (a) Ac₂O, cat. DMAP, Py, 14 h, 94%; (b) [Ir], H₂, THF, 4 h, then I₂, THF/H₂O (3:1), 16 h, 85%; (c) CCl₃CN, Cs₂CO₃, CH₂Cl₂, 60 min, then TMS-SMe, TMSOTf (5 mol %), 16 h, 50% for **53**, 31% for **54**; (d) MeONa, MeOH, 90 min, 91%.


was formed (not shown), indicating that blocking $4_{\rm C}$ -OH does not facilitate any alternative glucosylation at another position.

A novel set of CD acceptor disaccharides, in this case differing from substrate 1 at their reducing end, was also envisioned to eliminate the possible steric hindrance of the allyl group with some amino acid residues constituting the active site that could prevent glucosylation by NpAS (docking results not shown). For that reason, the allyl aglycon in disaccharide 1 was replaced while keeping in mind that any group introduced at the anomeric position of the D residue should provide an access to a CD donor. On the one hand, introduction of a smaller methylthio group gave disaccharide 8, and on the other hand, the allyl moiety in the key precursor 1 was simply cleaved to give the reducing analogue 9, the opened form of which could lead to a complete rearrangement of the substrate inside the enzyme active site. Hence, per-acetylation of disaccharide 1 gave fully protected 51 (94%), and subsequent deallylation and reaction with methyl trimethylsilyl sulfide gave rise to mainly oxazoline 53 (50%) but also to the expected methyl thioglycoside 54, albeit in an unoptimized 31% yield (Scheme 11). Finally, methanolysis gave the deprotected disaccharide 8 (91%).

For the preparation of analogue 9, direct deallylation of disaccharide 1 was attempted under several conditions,

including [Ir]/H₂/I₂ or PdCl₂/AcONa/AcOH, but none of them proved successful. Moreover, methanolysis of lactol 52 mediated by sodium methoxide or K₂CO₃ resulted in complete disaccharide degradation. Additionally, using the same conditions as for pentasaccharide 38, deallylation of di-Oisopropylidene 48 followed by acidic hydrolysis gave the expected lactol 9, albeit in poor yield (15% over two steps) (Scheme 12A). For those reasons, an alternative route was used (Scheme 12B). Thus, per-silvlation of allyl glycoside 1 gave the fully protected intermediate 55 (86%). NMR data revealed a 3:2 equilibrium between two rotamers coexisting owing to the bulkiness of the five TBS groups. Deallylation of the persilvlated 55 was uneventful (84%), and consecutive desilylation under mild conditions⁸⁵ provided the desired disaccharide 9 in an acceptable 70% yield. In contrast to its protected precursor, this novel potential acceptor substrate did not show any conformational constraints as inferred from NMR data.

Having disaccharides modified at their reducing end, 8 and 9, in hand, we examined their potential as acceptor substrates for NpAS under standard conditions in the presence of excess sucrose. The LC-MS profiles of the enzymatic reaction mixtures revealed that NpAS could not glucosylate these novel CD analogues (not shown), indicating that the reduction Scheme 12. Synthesis of the Reducing Disaccharide 9^a



^aA: from 48. Reagents and conditions: (a) [Ir], H₂, THF, 75 min, then I₂, THF/H₂O (3:1), 3 h; (b) AcOH/H₂O 1:1, 80 °C, 3 h, 15% (over two steps). B: from 1. Reagents and conditions: (a) TBSOTf, Py 60 °C, 15 h, 86%; (b) [Ir], H₂, THF, 2.5 h then I₂, THF/H₂O (2:1), 60 min, 84%; (c) Et₃N·3HF, THF, 50 °C, 26 h, 70%.

of the substituent size at C-1 did not influence the outcome of the enzymatic process.

It can be inferred from these results that non-natural acceptor substrate recognition by available biocatalysts is not a clear-cut process and that finding native glucansucrases able to glucosylate acceptor 1 at 4_D -OH as in *S. flexneri* type I or at 6_D -OH as in *S. flexneri* type I or at 6_D -OH as in *S. flexneri* type IV is not straightforward. In such particular cases, enzyme engineering technologies combined with computer-aided design remain the best option. The potential of these strategies has recently been illustrated to reshape the active site of *NpAS* and generate catalysts to effect glucosylation of non-natural monosaccharide acceptor ⁸⁶ with the requested stereo- and regiospecificities to achieve the chemo-enzymatic synthesis of other serotype-specific *S. flexneri* oligosaccharides.

CONCLUSION

This study is part of a program aimed at developing a synthetic carbohydrate-based vaccine against shigellosis. Toward this aim, the development of highly convergent synthetic strategies to several oligosaccharides identified as powerful functional mimics of a selected set of S. flexneri type specific O-SPs was undertaken. In addition to the study of purely chemical synthetic routes to the target oligosaccharides, we are investigating original chemo-enzymatic strategies involving an early enzymatic α -D-glucosylation step by use of tailored glucansucrases acting on non-natural lightly protected acceptors. Herein, we have reported the four-step chemical conversion of trisaccharide 2, obtained from the GBD-CD2mediated α -D-glucosylation at OH-4_C of disaccharide 1, into a fully orthogonally protected ECD intermediate 3. Differentiation between hydroxyl groups in trisaccharide 3 resulted from the selective benzoylation of primary alcohols under controlled conditions on the one hand and from the efficient selective isopropylidenation of cis-vicinal diols on the other hand. Trisaccharide 3 evolved into trichloroacetimidate 22 and into an acceptor, paving the way for chain elongation. While the former was easily validated as a donor to give pentasaccharide 24, the identification of a suitable ECD acceptor revealed important steric hindrance at OH-3_C. The latter issue was

overcome by the use of a small acetyl protecting group at OH- $2_{\rm C}$ providing acceptor 27. Efficient chain elongation at OH- $3_{\rm C}$ of acceptor 27 with residues B and A, respectively, provided the fully protected pentasaccharide 38. Following conversion of this key intermediate into PTFA donor 44 and acceptor 42, a [5 +5] glycosylation step gave the fully protected decasaccharide 46 in high yield, which was next completely deprotected into the known aminoethyl-equipped glycoside 5. This achievement demonstrates the feasibility of the programmed chemoenzymatic synthesis of S. flexneri oligosaccharides by use of glucansucrases in combination with carefully designed lightly protected acceptors, a disaccharide in this case. Broadening the programmed chemo-enzymatic concept onto four analogues of acceptor 1 also showed the limits of exploiting enzyme-natural promiscuity and that enzyme engineering toward novel tailored biocatalysts is required to address other S. flexneri serotypes.

EXPERIMENTAL SECTION

Chemical Synthesis. Purchased reagents and solvents were used as received. Air- and moisture-sensitive reactions were performed in dried glassware under argon. Anhydrous toluene, Et₂O, DCE, CH₂Cl₂, THF, DMF, MeCN, MeOH, and Py were delivered and stored on molecular sieves (MS). NaH (60% dispersion in mineral oil) was washed with anhyd pentane under a stream of argon before use. 4 Å MS were activated before use by heating at 250 °C under vacuum. Analytical TLC was performed with silica gel 60 F254, 0.25 mm precoated TLC plates. Compounds were visualized using UV₂₅₄ and/ or charring with orcinol $(1 \text{ mg} \cdot \text{mL}^{-1})$ in 10% aq H₂SO₄. Flash column chromatography was carried out using silica gel (particle size 40-63 μ m or 15–40 μ m). NMR spectra were recorded at 303 K and at 400 MHz (¹H) and 100 MHz (¹³C) equipped with a Broadband Observe probe. Signal assignments were based on ¹H, COSY, DEPT-135, HSQC, ¹³C, ¹³C gated decoupling, and HMBC experiments. Signals are reported as m (multiplet), s (singlet), d (doublet), t (triplet), pt (pseudo triplet), dd (doublet of doublet), dq (doublet of quadruplet), br s (broad singlet), br d (broad doublet), and br t (broad triplet), and coupling constants are reported in hertz (Hz). Spectra were recorded in $CDCl_3$, CD_3OD , $DMSO-d_6$, and D_2O . Chemical shifts are reported in ppm (δ) relative to residual solvent peak, CHCl₃ in the case of CDCl₃, MeOH in the case of CD₃OD, HOD and 4,4-dimethyl-4silapentane-1-sulfonic acid (DSS) in the case of D_2O , and DMSO in the case of DMSO- d_{67} at 7.26/77.16, 3.31/49.0, 4.79/0.0, and 2.50/ 39.5 ppm for the ¹H and ¹³C spectra, respectively. Of the two magnetically nonequivalent geminal protons at C-6, the one resonating at lower field is denoted H-6a, and the one at higher field is denoted H-6b. Sugar residues are serially lettered according to the lettering of the repeating unit of the S. flexneri 2a O-SP and identified by a subscript in the listing of signal assignments. HRMS were recorded in the positive-ion electrospray ionization (ESI+) mode. Solutions were prepared using 1:1 MeCN/H2O containing 0.1% formic acid or MeOH/water containing 10 mM ammonium acetate in the case of sensitive compounds. HR-MALDI-TOF-MS were recorded in the positive-ion reflector mode using 2,5-dihydroxybenzoic acid as the matrix. Solutions were prepared in MeCN/0.1% aq TFA. Optical rotations were obtained using the sodium D line at ambient temperature.

Methyl (4,6-O-*Isopropylidene-α-D-glucopyranosyl*)-(1→4)-2,3-O*isopropylidene-α-L-rhamnopyranoside* (11). To a solution of disaccharide 10⁵⁵ (1.10 g, 3.23 mmol) in a 1:1 mixture of acetone and DMF (9 mL) were added DMP (2.4 mL, 19.5 mmol, 6.0 equiv) and *p*-TSA (37 mg, 0.19 mmol, 0.06 equiv). The reaction mixture was stirred at rt for 7.5 h. Et₃N was added, and volatiles were evaporated and coevaporated repeatedly with water, MeOH, and CH₂Cl₂ under vacuum. Column chromatography of the residue (CH₂Cl₂/MeOH, 100:0 → 95:5) gave the di-O-isopropylidene 11 (1.17 g, 2.78 mmol, 86%) as a white foam: $R_f = 0.32$ (CH₂Cl₂/MeOH 9.5:0.5); [*α*]²³_D = 66.4 (*c* 1.0; CHCl₃); ¹H NMR (CDCl₃) δ 4.98 (d, $J_{1,2} = 4.1$ Hz, 1H, H-1_E), 4.84 (s, 1H, H-1_C), 4.15–4.10 (m, 2H, H-2_C) H-3_C), 3.90–3.84

(m, 2H, H-5_E, H-6a_E), 3.78–3.68 (m, 3H, H-3_E, H-5_C, H-6b_E), 3.59 (dt, $J_{2,3} = 9.4$ Hz, 1H, H-2_E), 3.52 (pt, $J_{3,4} = J_{4,5} = 9.2$ Hz, 1H, H-4_E), 3.40 (dd, $J_{4,5} = 9.8$ Hz, $J_{3,4} = 6.8$ Hz, 1H, H-4_C), 3.37 (s, 3H, OCH₃), 2.72 (br s, 1H, OH_{3E}), 2.24 (d, $J_{2,OH} = 9.4$ Hz, OH_{2E}), 1.51 (s, 3H, H_{iPr}), 1.50 (s, 3H, H_{iPr}), 1.44 (s, 3H, H_{iPr}), 1.35 (s, 3H, H_{iPr}), 1.33 (d, $J_{5,6} = 6.3$ Hz, 1H, H-6_C); ¹³C NMR (CDCl₃) δ 109.4 (C_{iPr-C}), 99.8 (C_{iPr-E}), 99.2 (C-1_E), 98.1 (C-1_C), 80.7 (C-4_C), 76.7 (C-2_C), 76.0 (C-3_C), 73.4 (2C, C-2_E, C-4_E), 72.4 (C-3_E), 64.8 (C-5_C), 63.5 (C-5_E), 62.4 (C-6_E), 55.0 (OCH₃), 29.2, 28.2, 26.5, 19.3 (4C, C_{iPr}), 17.8 (C-6_C); HRMS (ESI⁺) *m*/*z* calcd for C₁₉H₃₂O₁₀Na [M + Na]⁺ 443.1893, found 443.1861.

Methyl α -D-Glucopyranosyl-(1 \rightarrow 4)-2,3-O-isopropylidene- α -Lrhamnopyranoside (12). A solution of di-O-isopropylidene derivative 11 (246 mg, 583 μ mol) in 50% aq AcOH (2.0 mL) was stirred at 0 °C for 3.5 h and then at rt for 1 h. Toluene was added, and volatiles were evaporated. The residue was purified by column chromatography $(CH_2Cl_2/MeOH, 100:0 \rightarrow 90:10)$ to give the mono-O-isopropylidene 12 (199 mg, 523 μ mol, 89%) as a white foam: $R_f = 0.26$ (CH₂Cl₂/ MeOH 9:1); $[\alpha]_{D}^{23} = 65.0$ (c 1.0; CHCl₃); ¹H NMR (DMSO-d₆) δ 4.79-4.77 (m, 3H, H-1_C, H-1_F, OH_{4E}), 4.73-4.71 (m, 2H, OH_{2E}) OH_{3E}), 4.17–4.14 (m, 1H, OH_{6E}), 4.08 (d, $J_{2,3} = 5.7$ Hz, 1H, H-2_C), 3.95 (br t, 1H, H-3_C), 3.63–3.48 (m, 4H, H-5_C, H-5_E, H-6a_E, H-6b_E), 3.39 (dt, $J_{2,3} = 9.4$ Hz, $J_{1,2} = 4.7$ Hz, 1H, H-2_E), 3.26-3.14 (m, 3H, H- $4_{\rm C}$, H- $3_{\rm E}$, H- $4_{\rm E}$), 1.42 (s, 3H, H_{iPr}), 1.26 (d, $J_{5.6}$ = 6.3 Hz, 1H, H- $6_{\rm C}$), 1.25 (s, 3H, H_{iPr}); ¹³C NMR (DMSO-*d*₆) δ 108.3 (C_{iPr}), 99.7 (C-1_E), 97.1 (C-1_c), 79.9 (C-4_c), 76.6 (C-3_c), 75.3 (C-2_c), 73.1 (C-2_E), 72.1 $(2C, C-3_{E}, C-5_{E}), 69.5 (C-4_{E}), 64.7 (C-5_{C}), 60.1 (C-6_{E}), 54.1$ (OCH₃), 27.9, 26.2 (2C, C_{iPr}), 17.3 (C-6_C); HRMS (ESI⁺) m/z calcd for $C_{16}H_{28}O_{10}Na [M + Na]^+$ 403.1580, found 403.1625; *m*/*z* calcd for $C_{32}H_{56}O_{20}Na$ [2 M + Na]⁺ 783.3263, found 783.3432.

Allyl (4,6-O-Isopropylidene- α -D-glucopyranosyl)-(1 \rightarrow 4)-(2,3-Oisopropylidene- α - ι -rhamnopyranosyl)-(1 \rightarrow 3)-2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido- β -D-glucopyranoside (13) and Allyl (2,3:4,6-Di-O-isopropylidene- α -D-glucopyranosyl)-(1 \rightarrow 4)-(2,3-O-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido- β -D-glucopyranoside (14). To a solution of trisaccharide 2 (299 mg, 0.44 mmol) in acetone (10 mL), stirred under an argon atmosphere, were added CSA (20 mg, 0.09 mmol, 0.2 equiv) and 2-methoxypropene (253 µL, 2.64 mmol, 6.0 equiv). After the mixture was stirred for 2 h at rt, Et₃N (13 μ L, 0.09 mmol, 0.2 equiv) was added and the reaction mixture was concentrated. The residue was purified by column chromatography (cHex/EtOAc, 70:30 \rightarrow 50:50 to elute the first compound then 30:70 \rightarrow 0:100 to elute the second compound) to give the fully protected trisaccharide 14 (143 mg, 0.17 mmol, 39%), followed by diol 13 (171 mg, 0.22 mmol, 49%). The two compounds were isolated as white amorphous solids. Diol 13: $R_{f} = 0.20$ (cHex/EtOAc 3:7); $[\alpha]_{D}^{23} = +26$ (c 1.0; CHCl₃); ¹H NMR (\dot{CDCl}_3) δ 6.70 (d, $J_{NH,2}$ = 8.6 Hz, 1H, NH), 5.88-5.78 (m, 1H, CH=CH₂), 5.29-5.24 (m, $J_{\text{trans}} = 17.3$ Hz, 1H, CH=CH₂), 5.21–5.18 (m, J_{cis} = 10.4 Hz, 1H, CH=CH₂), 5.06 (s, 1H, H-1_C), 4.97 (d, $J_{1,2}$ = 4.2 Hz, 1H, H-1_E), 4.75 (d, $J_{1,2}$ = 8.4 Hz, 1H, H-1_D), 4.35–4.30 (m, 1H, -OCH_{2All}), 4.11–4.04 (m, 4H, -OCH_{2All}) H-2_C, H-3_C, H-3_D), 4.00-3.94 (m, 2H, H-6a_D, H-5_C), 3.89-3.78 (m, 3H, H-6b_D, H-6a_E, H-5_E), 3.77–3.64 (m, 4H, H-4_D, H-6b_E, H-2_D, H- 3_E), 3.62–3.56 (m, 1H, H- 2_E), 3.51 (pt, $J_{3,4} = J_{4,5} = 9.2$ Hz, 1H, H- 4_E), 3.38-3.31 (m, 2H, H-4_C, H-5_D), 2.58 (bs, 1H, OH), 2.05 (bs, 1H, OH), 1.51 (s, 6H, H_{iPr}), 1.45 (s, 3H, H_{iPr}), 1.44 (s, 3H, H_{iPr}), 1.41 (s, 3H, H_{iPr}), 1.27 (bs, 6H, H-6_C, H_{iPr}); ¹³C NMR (CDCl₃) δ 162.2 (NHCO), 133.4 (CH=CH₂), 118.4 (CH=CH₂), 109.3, 99.9, 99.8 (3C, C_{iPr}), 99.4 (C-1_D), 99.2 (C-1_E), 98.1 (C-1_C), 92.6 (CCl₃), 80.8 $(C-4_{C})$, 76.5, 76.4, 76.0 (3C, C-2_C, C-3_C, C-3_D), 73.5 (C-4_E), 73.4 (C-2_E), 73.0 (C-4_D), 72.3 (C-3_E), 70.5 (OCH_{2All}), 67.6 (C-5_D), 65.3 (C- $5_{\rm C}$), 63.5 (C- $5_{\rm E}$), 62.3, 62.2 (2C, C- $6_{\rm D}$, C- $6_{\rm E}$), 59.0 (C- $2_{\rm D}$), 29.3, 29.2, 28.2, 26.5, 19.4, 19.3 (6C, C_{iPr}), 17.9 (C-6_C); HRMS (ESI⁺) *m/z* calcd for $C_{32}H_{48}Cl_3NO_{15}Na [M + Na]^+ 814.1987$, found 814.1950.

Fully protected 14: $R_f = 0.25$ (cHex/EtOAc 7:3); $[\alpha]^{23}_D = +16$ (c 1.0; CHCl₃); ¹H NMR (CDCl₃) δ 6.68 (d, $J_{NH,2} = 8.6$ Hz, 1H, NH), 5.88–5.78 (m, 1H, CH=CH₂), 5.29–5.24 (m, $J_{trans} = 17.3$ Hz, 1H, CH=CH₂), 5.22 (d, $J_{1,2} = 3.1$ Hz, 1H, H-1_E), 5.21–5.18 (m, $J_{cis} =$ 10.5 Hz, 1H, CH=CH₂), 5.07 (s, 1H, H-1_C), 4.75 (d, $J_{1,2} = 8.4$ Hz, 1H, H-1_D), 4.35–4.30 (m, 1H, $-OCH_{2All}$), 4.13–4.03 (m, 4H, H-2_C, $-OCH_{2All}$, H-3_C, H-3_D), 4.00–3.94 (m, 3H, H-3_E, H-5_C, H-6a_D), 3.90–3.72 (m, 6H, H-2_D, H-4_E, H-5_E, H-6b_D, H-6a_E, H-6b_E), 3.66 (pt, J = 9.3 Hz, 1H, H-4_D), 3.48 (dd, $J_{2,3} = 9.1$ Hz, 1H, H-2_E), 3.38–3.30 (m, 2H, H-4_C, H-5_D), 1.54 (s, 3H, H_{iPr}), 1.50 (s, 3H, H_{iPr}), 1.44 (bs, 9H, H_{iPr}), 1.41 (s, 3H, H_{iPr}), 1.40 (s, 3H, H_{iPr}), 1.28 (s, 3H, H_{iPr}), 1.24 (d, $J_{5,6} = 6.3$ Hz, 3H, H-6_C); ¹³C NMR (CDCl₃) δ 162.1 (NHCO), 133.4 (CH=CH₂), 118.4 (CH=CH₂), 111.5, 109.3 (2C, C_{iPr-C}), 99.9, 99.8 (2C, C_{iPr-D}), 99.4 (C-1_D), 98.7 (C-1_E), 97.9 (C-1_C), 92.6 (CCl₃), 82.2 (C-4_C), 77.3 (C-2_E), 76.8, 76.0, 75.5 (3C, C-2_C, C-3_C, C-3_D), 74.1 (C-3_E), 73.9 (C-4_E), 73.0 (C-4_D), 70.6 (OCH_{2All}), 67.7 (C-5_D), 65.3 (C-5_C), 65.2 (C-5_E), 62.6 (C-6_D), 62.3 (C-6_E), 59.2 (C-2_D), 29.2 (2C, C_{iPr}), 28.2, 27.1, 26.5, 26.4, 19.4, 19.3 (6C, C_{iPr}), 17.5 (C-6_C); HRMS (ESI⁺) *m*/*z* calcd for C₃₅H₅₂Cl₃NO₁₅Na [M + Na]⁺ 854.2300, found 854.2335.

Allyl α -D-Glucopyranosyl-(1 \rightarrow 4)-(2,3-O-isopropylidene- α -L-rhamnopyranosyl)- $(1 \rightarrow 3)$ -2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido- β -D-glucopyranoside (15). A suspension of fully protected 14 (342 mg, 411 μ mol) in AcOH/H₂O (1:1 v/v, 6 mL) was stirred at rt for 15 h. The reaction mixture was concentrated and then repeatedly coevaporated with cyclohexane and toluene. The residue was purified by column chromatography (CH₂Cl₂/MeOH, 95:5 \rightarrow 80:20) to elute first tetraol 15 (63 mg, 85 μ mol, 20%) as a white amorphous solid and then hexaol 17 (191 mg, 268 μ mol, 65%) as a white amorphous solid: $R_{f} = 0.66 (CH_{2}Cl_{2}/MeOH 8.5:1.5); [\alpha]^{23}_{D} = +29 (c 1.0; CHCl_{3}); {}^{1}H$ NMR (MeOD) δ 5.92–5.83 (m, 1H, CH=CH₂), 5.31–5.25 (m, J_{trans} = 17.2 Hz, 1H, CH= CH_2), 5.17–5.13 (m, J_{cis} = 10.5 Hz, 1H, CH= CH_2), 5.07 (br s, 1H, H-1_C), 4.92 (d, $J_{1,2}$ = 3.8 Hz, 1H, H-1_E), 4.69-4.67 (m, 1H, H-1_D), 4.33-4.27 (m, 1H, -OCH_{2All}), 4.12-4.05 (m, 3H, H-2_C, H-3_C, -OCH_{2All}), 4.04-3.97 (m, 1H, H-5_C), 3.96-3.90 (m, 3H, H-2_C, H-3_C, H-6a_D), 3.87–3.84 (m, 2H, H-5_E, H-6b_D), 3.80– 3.76 (m, 2H, H-6a_E, H-6b_E), 3.71-3.62 (m, 2H, H-4_D, H-3_E), 3.47-3.40 (m, 2H, H-2_E, H-4_E), 3.37–3.29 (m, 2H, H-4_C, H-5_D), 1.56 (s, 3H, H_{iPr}), 1.49 (s, 3H, H_{iPr}), 1.43 (s, 3H, H_{iPr}), 1.31 (d, $J_{5.6} = 6.2$ Hz, 3H, H-6_C), 1.26 (s, 3H, H_{iPr}); ¹³C NMR (MeOD) δ 164.4 (NHCO), 135.1 (CH=CH₂), 117.5 (CH=CH₂), 110.1 (C_{iPr-C}), 101.6 (C-1_D), 101.5 (C-1_E), 101.0 (C_{iPr-D}), 99.4 (C-1_C), 99.4 (CCl₃), 82.5 (C-4_C), 78.7 (C-3_D), 78.2 (C-3_C), 77.3 (C-2_C), 74.8 (C-3_D), 74.1 (C-4_D), 73.7 (C-2_E), 73.2 (C-5_E), 71.3 (2C, C-4_E, OCH_{2All}), 68.7 (C-5_D), 66.6 (C- $5_{\rm C}$), 63.1 (C-6_D), 62.1 (C-6_E), 59.4 (C-2_D), 29.6, 28.5, 26.6, 19.3 (4C, C_{iPr}), 18.3 (C-6_C); HRMS (ESI⁺) m/z calcd for $C_{29}H_{44}Cl_3NO_{15}Na$ [M + Na]⁺ 774.1674, found 774.1688.

Allyl (2,3,4,6-Tetra-O-acetyl- α -D-glucopyranosyl)-(1 \rightarrow 4)-(2,3-Oisopropylidene- α - ι -rhamnopyranosyl)- $(1 \rightarrow 3)$ -2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido- β -D-glucopyranoside (16). To a solution of tetraol 15 (267 mg, 354 µmol) in anhyd Py (10 mL), stirred under an argon atmosphere, was added DMAP (4 mg, 33 μ mol, 0.1 equiv). The reaction mixture was cooled to 0 °C, acetic anhydride (1.0 mL, 10.6 mmol, 30 equiv) was added, and the reaction mixture was allowed to warm to rt. After being stirred for 2 h, the reaction mixture was cooled to 0 $^\circ\text{C}\textsc{,}$ and the reaction was quenched by slow addition of MeOH (10 mL). Volatiles were evaporated, and the remaining Py was removed by repeated coevaporation with toluene. The residue was purified by column chromatography (cHex/EtOAc, $75:25 \rightarrow 60:40$) to give tetra-acetate 16 (283 mg, 307 μ mol, 87%) as a white amorphous solid: $R_f = 0.46$ (cHex/EtOAc 1:1); $[\alpha]_D^{23} = +49$ (c 1.0; CHCl₃); ¹H NMR (CDCl₃) δ 6.75 (d, $J_{NH,2}$ = 8.7 Hz, 1H, NH), 5.87-5.78 (m, 1H, CH=CH₂), 5.47 (pt, J = 9.6 Hz, 1H, H-3_E), 5.29-5.23 (m, $J_{\text{trans}} = 17.2$ Hz, 1H, CH=CH₂), 5.21-5.17 (m, $J_{\text{cis}} = 10.4$ Hz, 1H, CH=CH₂), 5.14 (pt, J = 9.6 Hz, 1H, H-4_E), 5.08 (d, $J_{1,2} = 3.8$ Hz, 1H, H-1_E), 5.05 (s, 1H, H-1_C), 4.92 (dd, $J_{2,3}$ = 10.2 Hz, 1H, H-2_E), 4.73 (d, $J_{1,2} = 8.4$ Hz, 1H, H-1_D), 4.36–4.27 (m, 3H, H-5_E, H-6a_E) -OCH_{2All}), 4.10–4.03 (m, 5H, H-2_C, H-3_C, H-3_D, H-6b_E, -OCH_{2All}), 3.97-3.89 (m, 2H, H-6a_D, H-5_C), 3.84-3.73 (m, 2H, H-2_D, H-6b_D), 3.66 (pt, J = 9.3 Hz, 1H, H-4_D), 3.33 (dt, $J_{5,6}$ = 5.3 Hz, 1H, H-5_D), 3.25 $(dd, J_{4,5} = 10.3 \text{ Hz}, J_{3,4} = 7.0 \text{ Hz}, 1\text{H}, \text{H-4}_{\text{C}}), 2.08, 2.02, 2.01, 2.00 (4s, 10.1)$ 12H, H_{Ac}), 1.54, 1.46, 1.42, 1.39 (4s, 12H, H_{iPr}), 1.12 (d, $J_{5,6}$ = 6.1 Hz, 3H, H-6_C); ¹³C NMR (CDCl₃) δ 171.0, 170.4, 169.9, 169.7 (4C, C_{Ac}), 162.1 (NHCO), 133.3 (CH=CH₂), 118.4 (CH=CH₂), 109.4 (C_{iPr}), 99.8 (C_{iPr}), 99.4 (C-1_D), 97.8 (C-1_C), 96.9 (C-1_E), 92.5 (CCl₃), 87.8

 $\begin{array}{l} ({\rm C-4_C}), 77.4, 76.6, 76.0 \ (3{\rm C}, {\rm C-2_C}, {\rm C-3_C}, {\rm C-3_D}), 72.9 \ ({\rm C-4_D}), 70.9 \ ({\rm C-2_E}), 70.5 \ ({\rm OCH}_{2\ All}), 70.4 \ ({\rm C-3_E}), 68.3 \ ({\rm C-4_E}), 67.6 \ ({\rm C-5_D}), 67.4 \ ({\rm C-5_E}), 65.1 \ ({\rm C-5_C}), 62.2 \ ({\rm C-6_D}), 61.4 \ ({\rm C-6_E}), 59.0 \ ({\rm C-2_D}), 29.2, 28.3, 26.4 \ (3{\rm C}, {\rm C_{iPr}}), 20.9, 20.8, 20.7, 20.6 \ (4{\rm C}, {\rm C_{Ac}}), 19.4 \ ({\rm C_{iPr}}), 17.3 \ ({\rm C-6_C}); \ HRMS \ (ESI^+) \ m/z \ calcd \ for \ C_{37}H_{52}Cl_3NO_{19}Na \ [M + Na]^+ 942.2097, \ found \ 942.2035. \end{array}$

Allyl α -D-Glucopyranosyl-(1 \rightarrow 4)-(2,3-O-isopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2-deoxy-2-trichloroacetamido- β -D-glucopyranoside (17). Route 1. To a solution of diol 13 (100 mg, 126 μ mol) in MeCN (3 mL) were added I₂ (8 mg, 32 μ mol, 0.25 equiv) and H₂O (20 μ L). After the mixture was stirred for 2 h 45 at rt, Et₃N (100 μ L) was added, and the volatiles were removed under vacuum. The residue was purified by column chromatography (CH₂Cl₂/MeOH, 85:15) to give monoisopropylidene 17 (69 mg, 95 μ mol, 76%) as a white amorphous solid.

Route 2. MeONa (25 wt %, 230 µL, 1.01 mmol, 0.6 equiv) was added to a solution of tetraol 20 (1.54 g, 1.68 mmol) in anhyd MeOH (20 mL) stirred under an argon atmosphere. The reaction mixture was stirred for 3 h 40, and the reaction was quenched by addition of Dowex 50Wx8-200. The suspension was filtered over a pad of Celite, and volatiles were removed under vacuum. The residue was purified by column chromatography (CH₂Cl₂/MeOH, 90:10 \rightarrow 80:20) to give hexaol 17 (1.12 g, 1.57 mmol, 94%) as a white amorphous solid: $R_f =$ 0.36 (CH₂Cl₂/MeOH 4:1); $[\alpha]^{24}_{D}$ = +29.4 (c 1.0, MeOH); ¹H NMR $(D_2O) \delta 5.98-5.89 \text{ (m, 1H, CH=CH}_2), 5.37-5.32 \text{ (m, } J_{trans} = 17.3 \text{ (m, } J_{trans$ Hz, 1H, CH= CH_2), 5.30–5.26 (m, $J_{cis} = 10.5$ Hz, 1H, CH= CH_2), 5.13 (br s, 1H, H-1_c), 5.07 (d, $J_{1,2} = 3.8$ Hz, 1H, H-1_E), 4.79 (overlapped with D₂O, 1H, H-1_D), 4.41-4.36 (m, 1H, -OCH_{2All}), 4.28 (dd, $J_{3,4}$ = 7.5 Hz, $J_{2,3}$ = 5.4 Hz, 1H, H-3_C), 4.25–4.19 (m, 1H, $-OCH_{2All}$, 4.16 (d, 1H, H-2_C), 4.08 (dq, $J_{4,5} = 10.2$ Hz, 1H, H-5_C), 3.99-3.77 (m, 7H, H-6a_D, H-3_D, H-6a_E, H-4_D, H-6b_E, H-2_D, H-6b_D), 3.71 (pt, J = 9.5 Hz, 1H, H-3_E), 3.60–3.50 (m, 4H, H-5_D, H-2_E, H-4_E, H-5_E), 3.45 (dd, 1H, H-4_C), 1.56 (s, 3H, H_{iPr}), 1.36 (s, 3H, H_{iPr}), 1.31 (d, $J_{5,6} = 6.3$ Hz, 3H, H-6_C); ¹³C NMR (D₂O) δ 167.5 (NHCO), 135.6 (CH=CH₂), 121.3 (CH=CH₂), 112.8 (C_{iPr}), 102.1 (C-1_E), 101.5 (C-1_D), 100.7 (C-1_C), 94.2 (CCl₃), 84.4 (C-3_D), 82.7 (C-4_C), 79.0 (C-3_C), 78.7 (C-5_D), 78.3 (C-2_C), 75.3 (C-3_E), 74.1 (2C, C-5_E, C- 2_E), 73.4 (OCH_{2All}), 71.7 (C-4_E), 71.1 (C-4_D), 68.6 (C-5_C), 63.3 (C- $(C-6_{\rm E})$, 62.4 $(C-6_{\rm E})$, 59.9 $(C-2_{\rm D})$, 29.7, 28.1 $(2C, C_{\rm iPr})$, 18.8 $(C-6_{\rm C})$; HRMS (ESI⁺) m/z calcd for C₂₆H₄₀Cl₃NO₁₅Na [M + Na]⁺ 734.1361, found 734.1402.

Allyl α -L-Rhamnopyranosyl-(1 \rightarrow 3)-6-O-acetyl-2-deoxy-2-trichloroacetamido- β -D-glucopyranoside (18). Vinyl acetate (1.0 mL, 10.8. mmol, 54 equiv) and novozyme 435 (50 mg) were added to a solution of disaccharide 1 (102 mg, 0.20 mmol) in THF/Py (4:1 v/v, 5 mL) under an argon atmosphere. The reaction mixture was heated to 45 °C, stirred for 17 h, and then filtered on a pad of Celite, and the filtrate was concentrated. The residue was purified by column chromatography (CH₂Cl₂/MeOH 90:10) to give acetate 18 (97 mg, 175 μ mol, 88%) as a white amorphous solid: $R_f = 0.30$ (CH₂Cl₂/MeOH 9:1); $[\alpha]^{23}_{D} = -45 \ (c \ 1.0; \ MeOH); \ ^{1}H \ NMR \ (D_{2}O) \ \delta \ 5.97 - 5.87 \ (m, \ 1H, \ 1H)$ CH=CH₂), 5.36-5.31 (m, J_{trans} = 17.3 Hz, 1H, CH=CH₂), 5.29-5.26 (m, J_{cis} = 10.4 Hz, 1H, CH=CH₂), 4.91 (d, $J_{1,2}$ = 1.6 Hz, 1H, H- $1_{\rm C}$), 4.80 (overlapped with D₂O, 1H, H-1_D), 4.47 (dd, $J_{6a,6b}$ = 12.2 Hz, $J_{5.6a} = 2.0$ Hz, 1H, H-6a_D), 4.37-4.32 (m, 2H, H-6b_D), -OCH_{2All}), 4.22-4.16 (m, 1H, $-OCH_{2All}$), 4.00 (dq, $J_{4,5} = 9.7$ Hz, 1H, H-5_C), 3.93–3.79 (m, 3H, H-2_D, H-2_C, H-3_D), 3.76–3.65 (m, 3H, H-3_C, H- 4_{D_1} H- 5_{D}), 3.45 (pt, $J_{3,4}$ = 9.7 Hz, 1H, H- 4_{C}), 2.17 (s, 3H, H_{Ac}), 1.25 (d, $J_{5,6} = 6.3$ Hz, 3H, H-6_C); ¹³C NMR (D₂O) δ 176.7 (C_{Ac}), 167.4 (NHCO), 135.7 (CH=CH₂), 121.5 (CH=CH₂), 103.9 (C-1_C), 101.7 (C-1_D), 94.2 (CCl₃), 83.1 (C-3_D), 76.0 (C-5_D), 74.5 (C-4_C), 73.6 (-OCH_{2All}), 73.2 (C-2_C), 73.0 (C-3_C), 71.6 (C-5_C), 71.1 (C-4_D), 65.8 (C-6_D), 59.9 (C-2_D), 22.8 (C_{Ac}), 19.1 (C-6_C); HRMS (ESI⁺) m/zcalcd for $C_{19}H_{28}Cl_3NO_{11}Na [M + Na]^+ 574.0626$, found 574.0602.

Allyl (6-O-Benzoyl- α -D-glucopyranosyl)-(1 \rightarrow 4)- α -L-rhamnopyranosyl-(1 \rightarrow 3)-6-O-benzoyl-2-deoxy-2-trichloroacetamido- β -D-glucopyranoside (19). Trisaccharide 2 (1.82 g, 2.70 mmol) was suspended under an argon atmosphere in MeCN/acetone (1:1 v/v, 54 mL), and collidine (3.5 mL, 26.5 mmol, 9.8 equiv) was added. The reaction mixture was cooled to -40 °C, and benzoyl chloride was added (2.2 mL, 19.0 mmol, 7.0 equiv). After 46 h of stirring at this temperature, MeOH (20 mL) was added. After another 1 h, the reaction mixture was concentrated and repeatedly coevaporated with toluene, and the residue was purified by column chromatography (CH₂Cl₂/MeOH, $100:0 \rightarrow 90:10$). Fractions containing the expected dibenzoate were evaporated then taken up in CH₂Cl₂ (150 mL), washed with a 5% citric acid aq solution $(2 \times 20 \text{ mL})$ and brine $(1 \times 20 \text{ mL})$, and the aqueous layer was extracted twice with CH_2Cl_2 (2 × 10 mL). The combined organics were dried (Na₂SO₄), filtered, and concentrated to give dibenzoate 19 (1.55 g, 1.76 mmol, 65%) as a white amorphous solid: $R_f = 0.36$ (CH₂Cl₂/MeOH 9:1); $[\alpha]^{24}_{D} = +2.9$ (c 1.0, MeOH); ¹H NMR (MeOD) δ 8.07–8.05 (m, 4H, Ph), 7.64–7.59 (m, 2H, Ph), 7.51-7.47 (m, 4H, Ph), 5.90-5.80 (m, 1H, CH=CH₂), 5.25-5.19 (m, $J_{\text{trans}} = 17.3 \text{ Hz}$, 1H, CH=CH₂), 5.11–5.07 (m, $J_{\text{cis}} = 10.6 \text{ Hz}$, 1H, CH=CH₂), 4.96 (d, $J_{1,2}$ = 3.9 Hz, 1H, H-1_E), 4.90 (d, $J_{1,2}$ = 1.5 Hz, 1H, H-1_C), 4.69–4.64 (m, 3H, H-6a_F, H-1_D, H-6a_D), 4.53 (dd, $J_{6a,6b}$ = 11.9 Hz, $J_{5.6} = 5.5$ Hz, 1H, H-6b_D), 4.43 (dd, $J_{6a.6b} = 12.0$ Hz, $J_{5.6} = 4.9$ Hz, 1H, H-6b_E), 4.31–4.24 (m, 2H, H-5_E, $-OCH_{2All}$), 4.19 (dq, $J_{4,5}$ = 9.7 Hz, 1H, H-5_C), 4.09–4.04 (m, 1H, –OCH_{2All}), 3.88–3.80 (m, 4H, H-2_C, H-3_C, H-3_D, H-2_D), 3.68–3.64 (m, 2H, H-5_D, H-3_E), 3.60–3.55 (m, 1H, H-4_D), 3.51-3.43 (m, 3H, H-4_E, H-2_E, H-4_C), 1.34 (d, $J_{5,6}$ = 6.2 Hz, 3H, H-6_C); ¹³C NMR (MeOD) δ 168.2, 167.9 (2C, C_{Bz}), 164.4 (NHCO), 135.2 (CH=CH₂), 134.4, 134.3 (2C, Ph), 131.4, 131.3 (2C_{quat}, Ph), 130.7, 130.6, 129.7, 129.6 (8C, Ph), 117.6 (CH= CH₂), 102.7 (C-1_C), 101.2 (C-1_E), 101.0 (C-1_D), 94.2 (CCl₃), 83.6 (C-4_C), 82.6 (C-3_D), 75.5 (C-5_D), 74.7 (C-3_E), 73.6 (C-2_E), 72.6 (C- $2_{\rm C}$), 71.8 (C-4_E), 71.7 (C-5_E), 71.2 (OCH_{2All}), 71.1 (C-4_D), 70.8 (C- $3_{\rm C}$), 69.0 (C- $5_{\rm C}$), 65.3 (C- $6_{\rm E}$), 65.0 (C- $6_{\rm D}$), 58.8 (C- $2_{\rm D}$), 18.1 (C- $6_{\rm C}$); HRMS (ESI⁺) m/z calcd for C₃₇H₄₄Cl₃NO₁₇Na [M + Na]⁺ 902.1572, found 902.1567.

Allyl (6-O-Benzoyl- α -D-glucopyranosyl)-(1 \rightarrow 4)-(2,3-O-isopropylidene- α - ι -rhamnopyranosyl)-(1 \rightarrow 3)-6-O-benzoyl-2-deoxy-2-trichloroacetamido- β -D-qlucopyranoside (20). To a solution of dibenzoate 19 (806 mg, 0.91 mmol) in acetone (14 mL) stirred under an argon atmosphere were added CSA (85 mg, 0.37 mmol, 0.4 equiv) and DMP (450 μ L, 3.66 mmol, 4.0 equiv). After being stirred for 2 h at rt, Et₃N (100 μ L, 0.72 mmol, 0.8 equiv) was added, and the reaction mixture was concentrated. The residue was purified by column chromatography (CH₂Cl₂/MeOH, 96:4 \rightarrow 95:5, then 90:10) to give tetraol 20 (779 mg, 0.85 mmol, 92%) as a white amorphous solid, followed by the starting dibenzoate 19 (20 mg, 0.02 mmol, corrected yield: 95%): $R_{f} = 0.34 (CH_{2}Cl_{2}/MeOH 9.2:0.8); [\alpha]^{24}_{D} = +29.1 (c 1.0, CHCl_{3}); {}^{1}H$ NMR (MeOD) δ 8.09–8.03 (m, 4H, Ph), 7.65–7.60 (m, 2H, Ph), 7.53-7.47 (m, 4H, Ph), 5.91-5.81 (m, 1H, CH=CH₂), 5.26-5.20 $(m, J_{trans} = 17.3 \text{ Hz}, 1\text{H}, \text{CH}=CH_2), 5.12-5.08 (m, J_{cis} = 10.5 \text{ Hz}, 1\text{H},$ CH=CH₂), 5.10 (br s, 1H, H-1_C), 4.93 (d, $J_{1,2}$ = 3.9 Hz, 1H, H-1_E), 4.70–4.61 (m, 3H, H-6a_E, H-1_D, H-6a_D), 4.56–4.48 (m, 2H, H-6b_E, H-6b_D), 4.30–4.25 (m, 1H, -OCH_{2All}), 4.16–4.05 (m, 5H, -OCH_{2All}) $H-5_{C}$ $H-2_{C}$ $H-3_{C}$ $H-5_{E}$), 3.91-3.82 (m, 2H, $H-3_{D}$, $H-2_{D}$), 3.68-3.63(m, 2H, H-5_D, H-3_E), 3.61–3.54 (m, 2H, H-4_D, H-4_E), 3.43 (dd, $J_{2,3}$ = 9.5 Hz, 1H, H-2_E), 3.37–3.32 (m, 1H, H-4_C), 1.50 (s, 3H, H_{iPr}), 1.29 (d, $J_{5,6}$ = 6.2 Hz, 3H, H-6_C), 1.21 (s, 3H, H_{iPr}); ¹³C NMR (MeOD) δ 168.0, 167.8 (2C, C_{Bz}), 164.4 (NHCO), 135.1 (CH=CH₂), 134.4, 134.3 (2C, Ph), 131.4, 131.3 (2C_{quat}, Ph), 130.6, 130.5, 129.6 (8C, Ph), 117.5 (CH=CH₂), 110.1 (\dot{C}_{iPr}), 101.2 (C-1_E), 100.9 (C-1_D), 99.9 (C-1_C), 94.1 (CCl₃), 82.5 (C-3_D), 82.3 (C-4_C), 78.3 (C-2_C), 77.4 $(C-3_C)$, 75.5 $(C-5_D)$, 74.9 $(C-3_E)$, 73.7 $(C-2_E)$, 71.5 $(C-4_D)$, 71.2 $(C-4_D)$ $5_{\rm E}$), 71.1 (OCH_{2All}), 70.9 (C-4_E), 66.9 (C-5_C), 65.0 (C-6_D), 64.5 (C- $6_{\rm E}$), 58.9 (C-2_D), 28.6, 26.8 (2C, C_{iPr}), 17.7 (C-6_C); HRMS (ESI⁺) m/ z calcd for $C_{40}H_{48}Cl_3NO_{17}Na [M + Na]^+$ 942.1885, found 942.1855.

Allyl (2,3,4,6-Tetra-O-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 4)-(2,3-Oisopropylidene- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-4,6-di-O-benzyl-2deoxy-2-trichloroacetamido- β -D-glucopyranoside (3). NaH (272 mg, 11.3 mmol, 14 equiv) was added portionwise to a solution of hexaol 17 (578 mg, 0.81 mmol) in anhyd DMF (16 mL), stirred at -10 °C under an argon atmosphere. After 20 min, benzyl bromide (0.7 mL, 5.89 mmol, 7.3 equiv) was added dropwise. After another 4 h, while the bath temperature was slowly raised to 0 °C, MeOH (20 mL) was slowly added. The reaction mixture was acidified by dropwise addition of AcOH until pH = 6 was reached, and then volatiles were

evaporated under vacuum and coevaporated with toluene. The residue was taken up in EtOAc (100 mL) and washed with water $(2 \times 15 \text{ mL})$. The organic layer was dried with Na₂SO₄, filtered, and concentrated. The residue was purified by column chromatography (cHex/EtOAc, 90:10 \rightarrow 80:20) to give the fully protected trisaccharide 3 (795 mg, 0.63 mmol, 78%) as a white foam: $R_f = 0.42$ (cHex/EtOAc 7.6:2.4); $[\alpha]^{24}_{D} = +12.7$ (c 1.0, CHCl₃); ¹H NMR (CDCl₃) δ 7.41–7.25 (m, 29H, Ph, NH), 7.21-7.19 (m, 2H, Ph), 5.93-5.84 (m, 1H, CH= CH_2), 5.31–5.26 (m, J_{trans} = 17.2 Hz, 1H, $CH=CH_2$), 5.29 (s, 1H, H- $1_{\rm C}$), 5.21–5.17 (m, $J_{\rm cis}$ = 10.5 Hz, 1H, CH=CH₂), 5.00 (d, $J_{1,2}$ = 3.5 Hz, 1H, H-1_E), 4.96–4.52 (m, 13H, 12H_{Bn}, H-1_D), 4.39–4.34 (m, 1H, $-OCH_{2AII}$, 4.13 (pt, J = 6.2 Hz, 1H, H-3_D), 4.10–4.01 (m, 5H, H-2_D) $H-2_{C}$ $H-3_{C}$ $H-5_{E}$ $-OCH_{2All}$), 3.98 (pt, J = 9.5 Hz, 1H, $H-3_{E}$), 3.93-3.89 (m, 1H, H-5_D), 3.86-3.80 (m, 5H, H-5_C, H-4_E, H-6a_E, H-6a_D, H- $(6b_D)$, 3.73 (pt, J = 5.9 Hz, 1H, H-4_D), 3.67 (dd, $J_{6a,6b} = 10.4$ Hz, $J_{5,6b} = 10.4$ Hz, $J_{5,6$ 1.9 Hz, 1H, H-6b_E), 3.62 (dd, $J_{2,3}$ = 9.8 Hz, 1H, H-2_E), 3.38–3.32 (m, 1H, H-4_C), 1.45 (s, 3H, H_{iPr}), 1.28 (s, 3H, H_{iPr}), 1.25 (d, $J_{5.6}$ = 6.3 Hz, 3H, H-6_C); 13 C NMR (CDCl₃) δ 161.7 (NHCO), 138.9, 138.5, 138.1 (3C_{quat}, Ph), 138.0 (2C_{quat}, Ph), 137.2 (C_{quat}, Ph), 133.7 (CH=CH₂), 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6 (30C, Ph), 117.5 (CH=CH₂), 109.1 (C_{iPr}), 98.8 (C-1_E), 98.4 (C-1_D), 96.2 (C-1_C), 92.5 (CCl₃), 82.3 (C-3_E), 81.2 (C-4_C), 80.1 (C-2_E), 78.0 (C-4_E), 76.8 (C-4_D), 76.1, 76.0 (2C, C-2_C, C-3_C), 75.6, 75.2 (2C, C_{Bn}), 74.3 (C-5_D), 74.2, 73.9, 73.7, 73.6 (4C, C_{Bn}), 73.5 (C- 3_D), 70.6 (C- 5_E), 69.8 (C- 6_D), 69.7 (OCH_{2All}), 68.1 (C- 6_E), 66.2 (C-5_C), 53.7 (C-2_D), 28.2, 26.5 (2C, C_{iPt}), 17.4 (C-6_C); HRMS (ESI⁺) m/z calcd for C₆₈H₇₆Cl₃NO₁₅Na [M + Na]⁺ 1274.4178, found 1274.4186

2,3,4,6-Tetra-O-benzyl- α -D-glucopyranosyl- $(1 \rightarrow 4)$ -(2,3-O-isopropylidene- α - ι -rhamnopyranosyl)-(1 \rightarrow 3)-4,6-di-O-benzyl-2-deoxy-2trichloroacetamido- α/β -D-glucopyranose (21). 1,5-Cyclooctadienebis(methyldiphenylphosphine)iridium hexafluorophosphate (14 mg, 17 μ mol, 0.03 equiv) was dissolved in THF (5 mL) under an argon atmosphere. Hydrogen was bubbled through the solution for 20 min, causing the color to change from red to yellow. The solution was degassed by complete evaporation of the solvent under vacuum. The activated iridium complex was dissolved in THF (2 mL) under an argon atmosphere, and a solution of allyl glycoside 3 (619 mg, 494 μ mol) in THF (8 mL) was added. The reaction mixture was stirred for 2 h 30 at rt, and then a solution of iodine (238 mg, 938 μ mol, 1.9 equiv) in THF/water (10 mL, 4:1 v/v) was added. After 5 h, the excess iodine was quenched by addition of 10% aq sodium bisulfite (10 mL). The reaction mixture was concentrated under reduced pressure to remove THF, water (5 mL) was added, and the aqueous phase was extracted with CH_2Cl_2 (2 × 40 mL). The combined organics were dried (Na₂SO₄), filtered, and concentrated to dryness. Column chromatography of the residue (toluene/EtOAc, 90:10 \rightarrow 80:20) afforded lactol 21 (480 mg, 396 μ mol, 80%) as a colorless oil (lpha/eta, 9:1): $R_f = 0.32$ (α), 0.12 (β) (toluene/EtOAc 4:1). α : ¹H NMR $(CDCl_3) \delta$ 7.37–7.14 (m, 30H, Ph), 7.04 (d, $J_{NH,2}$ = 9.3 Hz, 1H, NH), 5.26–5.24 (m, 2H, H-1_D, H-1_C), 4.96 (d, $J_{1,2}$ = 3.5 Hz, 1H, H-1_E), 4.96–4.48 (m, 12H, H_{Bn}), 4.24 (pdt, $J_{2,3}$ = 9.8 Hz, $J_{1,2}$ = 3.5 Hz, 1H, H-2_D), 4.16–3.90 (m, 7H, H-3_D, H-2_C, H-3_C, H-5_D, H-5_E, H-3_E, H-3_E, H-3_E, H-3_E, H-3_D, H- $5_{\rm C}$), 3.81-3.76 (m, 2H, H-6a_E, H-4_E), 3.72 (dd, $J_{6a,6b} = 10.6$ Hz, $J_{5,6a} = 10.6$ Hz, J4.7 Hz, 1H, H-6a_D), 3.66–3.60 (m, 3H, H-6b_E, H-6b_D, H-4_D), 3.58 (dd, $J_{2,3} = 9.7$ Hz, 1H, H-2_E), 3.37 (dd, $J_{4,5} = 10.2$ Hz, $J_{3,4} = 7.2$ Hz, 1H, H-4_C), 3.20 (bs, 1H, OH), 1.42 (s, 3H, H_{iPr}), 1.23 (s, 3H, H_{iPr}), 1.16 (d, $J_{5.6} = 6.2$ Hz, 3H, H-6_C); ¹³C NMR (CDCl₃) δ 161.9 (NHCO), 138.9, 138.5 (2C_{quat}, Ph), 138.1 (2C_{quat}, Ph), 137.5, 137.4 (2C_{quat}, Ph), 128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6 (30C, Ph), 109.0 (C_{iPr}) , 98.8 $(C-1_E)$, 97.7 $(C-1_C)$, 92.4 (CCl_3) , 91.4 $(C-1_D)$, 82.2 $(C-3_E)$, 81.6 $(C-4_C)$, 80.1 $(C-2_E)$, 78.0 $(C-4_E)$, 77.4 $(C-4_E)$ (4_D) , 76.8 (C-2_C), 76.2 (C-3_C), 75.7 (C_{Bn}), 75.5 (C-3_D), 75.4, 75.2, 73.9, 73.6, 73.5 (5C, C_{Bn}), 70.9 (C-5_D), 70.6 (C-5_E), 68.7 (C-6_D), 68.1 $(C-6_E)$, 66.2 $(C-5_C)$, 55.8 $(C-2_D)$, 28.2, 26.5 $(2C, C_{iPr})$, 17.2 $(C-6_C)$; HRMS (ESI⁺) m/z calcd for $C_{65}H_{72}Cl_3NO_{15}Na$ [M + Na]⁻ 1234.3865, found 1234.3800.

2,3,4,6-Tetra-O-benzyl- α -D-glucopyranosyl- $(1 \rightarrow 4)$ -(2,3-O-isopropylidene- α -L-rhamnopyranosyl)- $(1 \rightarrow 3)$ -4,6-di-O-benzyl-2-deoxy-2trichloroacetamido- α/β -D-glucopyranosyl Trichloroacetimidate

(22). To a solution of lactol 21 (426 mg, 0.34 mmol) in anhyd DCE (4 mL) stirred at -10 °C and under argon atmosphere were added trichloroacetonitrile (170 µL, 1.70 mmol, 5.0 equiv) and DBU (15 μ L, 0.10 mmol, 0.3 equiv). The reaction mixture was stirred for 35 min at -10 °C and volatiles were evaporated at rt under reduced pressure. The residue was purified by column chromatography (toluene/EtOAc, 90:10 + 1% Et₃N) to give imidate 22 (322 mg, 0.24 mmol, 70%) as a white amorphous solid (α/β ratio 9:1), followed by lactol 21 (118 mg, 0.09 mmol, corrected yield: 93%). $R_f = 0.35$ (toluene/EtOAc 9:1 + 1% Et₃N). α : ¹H NMR (CDCl₃) δ 8.78 (s, 1H, C=NH), 7.39–7.19 (m, 30H, Ph), 7.10 (d, $J_{NH,2}$ = 8.9 Hz, 1H, NH), 6.45 (d, $J_{1,2}$ = 3.6 Hz, 1H, H-1_D), 5.31 (bs, 1H, H-1_C), 4.99 (d, $J_{1,2}$ = 3.3 Hz, 1H, H-1_E), 4.99 (d, J = 10.9 Hz, 1H, H_{Bn}), 4.90–4.45 (m, 12H, $11H_{Bny}$ H-2_D), 4.21 (pt, J = 9.6 Hz, 1H, H-3_D), 4.17-4.11 (m, 2H, H-2_C, H-3_C), 4.06–3.92 (m, 5H, H-5_D, H-5_E, H-3_E, H-4_D, H-5_C), 3.90– 3.79 (m, 3H, H-6a_D, H-6a_E, H-4_E), 3.73 (dd, $J_{6a,6b}$ = 10.9 Hz, $J_{5,6b}$ = 1.8 Hz, 1H, H-6b_D), 3.67 (dd, $J_{6a,6b} = 10.5$ Hz, $J_{5,6b} = 1.7$ Hz, 1H, H-6b_E), 3.62 (dd, $J_{2,3}$ = 9.8 Hz, 1H, H-2_E), 3.30 (dd, $J_{4,5}$ = 10.2 Hz, $J_{3,4}$ = 7.1 Hz, 1H, H-4_C), 1.45 (s, 3H, H_{iPr}), 1.27 (s, 3H, H_{iPr}), 1.24 (d, $J_{5.6} = 6.2$ Hz, 3H, H-6_C). ¹³C NMR (CDCl₃) δ 161.9 (NHCO), 160.3 (C= NH), 138.9, 138.6 (2 C_{quat} Ph), 138.1 (2 C_{quat} Ph), 137.8, 137.5 (2C_{quat}, Ph), 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6 (30C, Ph), 109.3 (C_{iPr}), 98.9 (C-1_E), 97.6 (C-1_C), 94.9 (C-1_D), 92.2 (C(O)CCl₃), 90.9 (C(NH)CCl₃), 82.2 (C-3_E), 81.2 $(C-4_{C})$, 80.1 $(C-2_{E})$, 78.0 $(C-4_{E})$, 77.0 $(C-3_{C})$, 76.2 $(2C, C-4_{D}, C-2_{C})$, 75.7, 75.6, 75.2 (3C, C_{Bn}), 75.0 (C-3_D), 74.2 (C_{Bn}), 73.8 (C-5_D), 73.7, 73.6 (2C, C_{Bn}), 70.6 (C-5_E), 68.2 (C-6_E), 67.9 (C-6_D), 66.8 (C-5_C), 55.2 (C-2_D), 28.2, 26.4 (2C, C_{iPr}), 17.3 (C-6_C).

Allyl (2,3,4,6-Tetra-O-benzyl- α -D-qlucopyranosyl)-(1 \rightarrow 4)-(2,3-Oisopropylidene- α - ι -rhamnopyranosyl)-(1 \rightarrow 3)-(4,6-di-O-benzyl-2deoxy-2-trichloroacetamido- β -D-glucopyranosyl)-(1 \rightarrow 2)-(3,4-di-Obenzyl- α - ι -rhamnopyranosyl)- $(1 \rightarrow 2)$ -3,4-di-O-benzyl- α - ι -rhamnopyranoside (24). A suspension of donor 22 (100 mg, 73.6 μ mol), acceptor 23 (57 mg, 80.1 µmol, 1.1 equiv), and freshly activated 4 Å MS (200 mg) in anhyd DCE (1 mL), was stirred for 15 min at rt under an argon atmosphere. The reaction mixture was cooled to -35°C, and TMSOTf (2 μ L, 7.7 μ mol, 0.1 equiv) was added. After themixture was stirred for 30 min at this temperature, Et₃N (10 μ L) was added, and then the reaction mixture was filtered on a pad of Celite. The filtrate was evaporated, and the residue was purified by column chromatography (toluene/EtOAc 95:5) to give pentasaccharide 24 (110 mg, 57.6 μ mol, 78%) as a white amorphous solid: R_f = 0.28 (toluene/EtOAc 9:1); $[\alpha]^{24}_{D} = +5.9$ (c 1.0; CHCl₃). ¹H NMR (CDCl₃) δ 7.41–7.18 (m, 50H, Ph), 7.06 (d, $J_{\rm NH,2}$ = 8.0 Hz, 1H, NH), 5.93-5.84 (m, 1H, CH=CH₂), 5.29-5.24 (m, 2H, CH=CH₂, H- $1_{\rm C}$), 5.21–5.18 (m, $J_{\rm cis}$ = 10.4 Hz, 1H, CH=CH₂), 5.04 (d, $J_{1,2}$ = 1.5 Hz, 1H, H-1_A), 5.00 (d, $J_{1,2}$ = 3.5 Hz, 1H, H-1_E), 4.94–4.39 (m, 22H, 20H_{Bn}, H-1_D, H-1_B), 4.16-4.11 (m, 1H, -OCH_{2All}), 4.10-4.03 (m, 5H, H-2_D, H-5_E, H-2_A, H-3_C, H-2_C), 3.99–3.87 (m, 5H, H-2_B, H-3_A, H-3_D, H-3_E, -OCH_{2All}), 3.85-3.77 (m, 5H, H-6a_E, H-4_E, H-5_A, H-5_C, H-3_B), 3.72–3.56 (m, 6H, H-5_D, H-2_E, H-6a_D, H-5_B, H-4_D, H-6b_E), 3.52 (dd, $J_{6a,6b}$ = 9.6 Hz, $J_{5,6b}$ = 3.6 Hz, 1H, H-6b_D), 3.47 (pt, J = 9.4 Hz, 1H, H-4_A), 3.37 (pt, J = 9.4 Hz, 1H, H-4_B), 3.29–3.25 (m, 1H, H- $4_{\rm C}$), 1.43 (s, 3H, $H_{\rm iPr}$), 1.31 (d, $J_{5,6}$ = 6.2 Hz, 6H, H-6_A, H-6_B), 1.23 (s, 3H, H_{iPr}), 1.19 (d, $J_{5,6}$ = 6.2 Hz, 3H, H-6_C); ¹³C NMR (CDCl₃) δ 161.7 (NHCO), 138.9, 138.7, 138.6, 138.5, 138.3, 138.2, 138.1, 138.0, 137.5 (10Cquat, Ph), 133.9 (CH=CH2), 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5 (50C, Ph), 117.2 (CH=CH₂), 109.0 (C_{iPr}), 101.5 (C-1_A), 101.2 (C-1_D, ${}^{1}J_{CH} =$ 162.3 Hz), 98.8 (C-1_E), 97.9 (C-1_B), 96.9 (C-1_C), 92.5 (CCl₃), 82.2 $(C-3_E)$, 81.6 $(C-4_C)$, 81.1 $(C-4_A)$, 80.6 $(C-4_B)$, 80.2 $(C-2_E)$, 79.5 $(C-4_B)$ 3_A), 79.2 (C-3_B), 78.0 (C-4_E), 76.9, 76.7, 76.4, 76.2, 76.1, 76.0, 75.8 (7C, C-5_D, C-4_D, C-3_D, C-3_C, C-2_C, C-2_B, C-2_A), 75.6, 75.5, 75.4, 75.1, 74.1, 74.0, 73.6, 73.5, 73.4, 71.5 (10C, C_{Bn}), 70.6 (C-5_E), 69.3 (C-6_D), 68.5 (C-5_B), 68.2 (C-6_E), 67.8 (2C, C-5_A, OCH_{2AII}), 66.0 (C-5_C), 56.4 $(C-2_D)$, 28.3 (C_{iPr}) , 26.6 (C_{iPr}) , 18.1 (2C, C-6_A, C-6_B), 17.3 $(C-6_C)$; HRMS (ESI⁺) m/z calcd for $C_{108}H_{120}Cl_3NO_{23}Na$ [M + Na] 1926.7214, found 1926.7100.

Allyl (2,3,4,6-Tetra-O-benzyl- α -D-glucopyranosyl)- $(1 \rightarrow 4)$ - $(\alpha$ -L-rhamnopyranosyl)- $(1 \rightarrow 3)$ -4,6-di-O-benzyl-2-deoxy-2-trichloroace-

tamido- β -D-glucopyranoside (25). To a solution of fully protected trisaccharide 3 (657 mg, 0.52 mmol) in CH2Cl2 (7 mL) was added TFA (50% aq, 3 mL). The biphasic mixture was vigorously stirred for 75 min and then repeatedly coevaporated with toluene and cyclohexane. The residue was purified by column chromatography (cHex/EtOAc, 70:30 \rightarrow 65:35) to give diol 25 (601 mg, 0.50 mmol, 94%) as a white amorphous solid: $R_f = 0.26$ (cHex/EtOAc 6.5:3.5); $[\alpha]^{24}_{D} = -4.1$ (c 1.0; CHCl₃); ¹H NMR (CDCl₃) δ 7.40–7.22 (m, 29H, Ph, NH), 7.18-7.15 (m, 2H, Ph), 5.95-5.85 (m, 1H, CH= CH₂), 5.33–5.28 (m, J_{trans} = 17.2 Hz, 1H, CH=CH₂), 5.23–5.17 (m, $J_{cis} = 10.5$ Hz, 1H, CH=CH₂), 5.16 (bs, 1H, H-1_C), 4.95 (d, $J_{1,2} = 3.7$ Hz, 1H, H-1_E), 4.92 (d, J = 11.0 Hz, 1H, H_{Bn}), 4.86 (d, J = 10.9 Hz, 1H, H_{Bn}), 4.78–4.49 (m, 11H, 10 H_{Bn} , H-1_D), 4.39–4.35 (m, 1H, $-OCH_{2All}$, 4.15 (pt, J = 7.1 Hz, 1H, H-3_D), 4.11–3.98 (m, 4H, H-2_C) H-2_D, H-3_F, -OCH_{2All}), 3.97-3.75 (m, 7H, H-4_D, H-3_C, H-6a_D, H-5_D, H-6b_D, H-5_E, H-5_C), 3.69–3.58 (m, 3H, H-2_E, H-6a_E, H-6b_E), 3.52 (pt, J = 9.5 Hz, 1H, H-4_E), 3.41 (pt, J = 9.1 Hz, 1H, H-4_C), 2.81 (bs, 1H, OH), 1.33 (d, $J_{5.6} = 6.1$ Hz, H-6_C); ¹³C NMR (CDCl₃) δ 161.8 (NHCO), 138.7, 138.1, 138.0, 137.9, 137.5, 137.4 (6C_{quat}, Ph), 133.7 (CH=CH₂), 128.6, 128.5, 128.2, 128.0, 127.9, 127.8, 127.7 (30C, Ph), 117.7 (CH= CH_2), 99.4 (C-1_E), 98.8 (C-1_C), 98.5 (C-1_D), 92.5 (CCl_3) , 86.0 $(C-4_C)$, 81.6 $(C-3_E)$, 79.9 $(C-2_E)$, 77.9 $(C-4_E)$, 76.4 $(C-4_E)$ 4_D), 75.7, 75.2 (2C, C_{Bn}), 75.1 (C-3_D), 74.4 (C-5_D), 74.1, 73.7, 73.6, 73.5 (4C, C_{Bn}), 71.4 (C-5_E), 70.8, 70.0 (2C, C-2_C, C-3_C), 69.9 (OCH_{2AII}) , 69.3 $(C-6_D)$, 68.7 $(C-6_E)$, 67.1 $(C-5_C)$, 55.2 $(C-2_D)$, 17.8 (C-6_C); HRMS (ESI⁺) m/z calcd for C₆₅H₇₂Cl₃NO₁₅Na [M + Na]⁺ 1234.3865, found 1234.3870.

Allyl (2,3,4,6-Tetra-O-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 4)-(2-O $benzoyl-\alpha-\iota$ -rhamnopyranosyl)-(1 \rightarrow 3)-4,6-di-O-benzyl-2-deoxy-2trichloroacetamido- β -D-glucopyranoside (26). To a solution of diol 25 (99 mg, 82 μ mol) in anhyd CH₂Cl₂ (200 μ L) and under an argon atmosphere were added trimethyl orthobenzoate (96 μ L, 559 μ mol, 6.8 equiv) and p-TSA (1 mg, 5 μ mol, 0.06 equiv). The reaction mixture was stirred for 20 min at rt, and 50% aq TFA (1 mL) was added. The reaction mixture was stirred for another 45 min before being repeatedly coevaporated with toluene. The residue was purified by column chromatography (cHex/EtOAc, 85:15 \rightarrow 70:30) to give alcohol 26 (89 mg, 68 μ mol, 82%) as a white amorphous solid: \vec{R}_{f} = 0.44 (cHex/EtOAc 7:3); $[\alpha]^{24}_{D} = +16.8$ (c 1.0; CHCl₃); ¹H NMR (CDCl₃) δ 8.06–8.04 (m, 2H, H_{Bz}), 7.63–7.58 (m, 1H, H_{Bz}), 7.50– 7.46 (m, 2H, H_{Bz}), 7.39–7.19 (m, 29H, Ph, NH), 7.17–7.13 (m, 2H, Ph), 5.96–5.86 (m, 1H, CH=CH₂), 5.44–5.43 (m, 1H, H-2_C), 5.33– 5.27 (m, $J_{\text{trans}} = 17.2$ Hz, 1H, CH=CH₂), 5.33-5.19 (m, 2H, H-1_C) CH=CH₂), 4.96 (d, $J_{1,2}$ = 3.7 Hz, 1H, H-1_E), 4.92–4.43 (m, 13H, $12H_{Bn}$, H-1_D), 4.40–4.34 (m, 1H, –OCH_{2All}), 4.28–4.22 (m, 1H, H-3_D), 4.11–3.97 (m, 5H, H-5_C, H-5_F, H-3_C, -OH, -OCH_{2All}), 3.92– 3.74 (m, 6H, H-4_D, H-5_D, H-6a_D, H-6b_D, H-3_E, H-2_D), 3.65–3.55 (m, 4H, H-4_E, H-2_E, H-6a_E, H-6b_E), 3.46 (pt, J = 9.0 Hz, 1H, H-4_C), 1.37 (d, $J_{5,6} = 6.2$ Hz, H-6_C); ¹³C NMR (CDCl₃) δ 165.9 (C_{Bz}), 161.9 (NHCO), 138.8, 138.2, 138.1, 138.0, 137.7, 137.5 ($6C_{quat}$, Ph), 133.7 ($CH=CH_2$), 133.3 (C_{Bz}), 130.1 (C_{quat} , C_{Bz}), 130.0 (C_{Bz}), 128.7, 128.6, 128.5, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7 (32C, Ph), 117.8 $(CH=CH_2)$, 99.3 $(C-1_E)$, 98.2 $(C-1_D)$, 97.2 $(C-1_C)$, 92.5 (CCl_3) , 85.7 $(C-4_{C})$, 81.8 $(C-3_{E})$, 80.1 $(C-2_{E})$, 77.9 $(C-4_{E})$, 76.7 $(C-4_{D})$, 75.7 (C_{Bn}), 75.5 (C-3_D), 75.2 (C_{Bn}), 74.4 (C-5_D), 74.2, 73.9, 73.7, 73.6 (4C, C_{Bn}), 72.6 (C-2_C), 71.5 (C-5_E), 70.1 (OCH_{2All}), 69.3 (C-6_D), 68.6 (C- $6_{\rm E}$), 68.5 (C-3_C), 67.7 (C-5_C), 55.9 (C-2_D), 18.1 (C-6_C); HRMS (ESI⁺) m/z calcd for C₇₂H₇₆Cl₃NO₁₆ [M + H]⁺ 1316.4308, found 1316.4205.

Allyl (2,3,4-Tri-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[2,3,4,6tetra-O-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 4)]-(2-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido- β -D-glucopyranoside (**36**). A suspension of acceptor **26** (82 mg, 62.2 μ mol), the known rhamnosyl donor⁷⁹ **34** (40 mg, 92.0 μ mol, 1.5 equiv), and freshly activated 4 Å MS (100 mg) in anhyd toluene (2 mL) was heated to 70 °C under an argon atmosphere. TMSOTf (1.0 μ L, 5.4 μ mol, 0.09 equiv) was added to the reaction mixture, which was stirred at 70 °C for 60 min and then cooled to rt. Et₃N (5 μ L) was added, and the mixture was filtered over a pad of Celite. The filtrate was concentrated to dryness, and the residue was purified by column chromatography (toluene/EtOAc, 95:5 \rightarrow 85:15) to give tetrasaccharide 36 (20 mg, 12.6 μ mol, 20%) as a white amorphous solid along with recovered acceptor 26 (57 mg, 43.5 μ mol, 70%): $R_f = 0.44$ (toluene/EtOAc 4:1); $[\alpha]^{24}_{D} = -4.0$ (c 1.0; CHCl₃); ¹H NMR $(CDCl_3) \delta 8.10-8.07 (m, 2H, H_{Bz}), 7.64-7.60 (m, 1H, H_{Bz}), 7.51-$ 7.47 (m, 2H, H_{Bz}), 7.39–7.26 (m, 28H, Ph, NH), 7.20–7.16 (m, 3H, Ph), 5.93–5.86 (m, 1H, CH=CH₂), 5.48 (br s, 1H, H-2_C), 5.34–5.16 (m, 6H, CH= CH_2 , H-1_C, H-2_B, H-3_B, H-1_E), 5.06 (br s, 1H, H-1_B), 4.97-4.90 (m, 2H, H_{Bn}, H-4_B), 4.86-4.50 (m, 11H, H_{Bn}), 4.41 (d, J =12.1 Hz, 1H, H_{Bn}), 4.37–4.25 (m, 3H, -OCH_{2All}, H-3_C, H-3_D), 4.10– 3.90 (m, 5H, -OCH_{2All}, H-2_D, H-3_E, H-5_C, H-5_E), 3.87-3.59 (m, 10H, H-2_E, H-4_C, H-4_D, H-4_E, H-5_B, H-5_D, H-6a_D, H-6b_D, H-6a_E, H-6b_E), 2.10 (s, 3H, H_{Ac}), 1.88, 1.86 (2s, 6H, H_{Ac}), 1.23 (d, $J_{5.6}$ = 5.9 Hz, 1H, H-6_C), 0.91 (br s, 3H, H-6_B); ¹³C NMR (partial, CDCl₃) δ 170.0, 169.8 (3C, C_{Ac}), 165.8 (C_{Bz}), 161.8 (NHCO), 139.0, 138.8, 138.5, 138.3, 138.2, 137.5 (6C_{quat}, Ph), 133.8 (CH=CH₂), 133.5 (C_{Bz}), 130.0 (C_{Bz}), 129.8 (C_{quat} , C_{Bz}), 128.6, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5 (32C, Ph), 117.8 (CH=CH₂), 98.2 (C-1_D), 96.1 (C-1_C), 92.6 (CCl₃), 81.8 (C-3_E), 81.0 (C-2_E), 78.0 $(C-4_E)$, 76.3 $(C-4_D)$, 75.6 (C_{Bn}) , 75.0 (C_{Bn}) , 74.5 $(C-5_D)$, 74.1, 73.8, 73.6, 73.2 (4C, C_{Bn}), 73.0 (C-2_B), 71.6 (C-5_E), 71.1 (C-4_B), 70.1 (OCH_{2All}) , 69.9 $(C-2_C)$, 69.4 $(C-6_E)$, 69.1 $(C-3_B)$, 69.0 $(C-6_D)$, 68.2 $(C-5_C)$, 67.2 $(C-5_B)$, 56.1 $(C-2_D)$, 21.0, 20.8, 20.7 (3C, C_{Ac}), 18.9 (C- $6_{\rm C}$), 17.2 (C- $6_{\rm B}$); HRMS (ESI⁺) m/z calcd for $C_{84}H_{92}Cl_3NO_{23}Na$ [M + Na]⁺ 1610.5023, found 1610.5002.

Allvl (3,4-Di-O-benzyl-2-O-levulinyl- α -L-rhamnopyranosyl)-(1 \rightarrow 2)-[2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 4)]-(α -L-rhamnopyranosyl)- $(1 \rightarrow 3)$ -4,6-di-O-benzyl-2-deoxy-2-trichloroacetami $do-\beta$ -D-glucopyranoside (37). A suspension of diol 25 (144 mg, 119 μ mol), the known rhamnosyl donor $\mathbf{28}^{71}$ (71 mg, 121 μ mol, 1.0 equiv), and freshly activated 4 Å MS (160 mg) in anhyd toluene (2.4 mL) was stirred for 10 min under an argon atmosphere. The reaction mixture was cooled to -15 °C, and TMSOTf (1.5 μ L, 5.8 μ mol, 0.05 equiv) was added. After the mixture was stirred for 10 min at -15 °C, Et_3N (10 μ L) was added, and the reaction mixture was filtered over a pad of Celite and concentrated to dryness. The residue was purified by column chromatography (toluene/EtOAc, 84:16) to give tetrasaccharide 37 (161 mg, 98.3 μ mol, 80%) as a white amorphous solid contaminated with trichloroacetamide: $R_f = 0.33$ (toluene/EtOAc 4:1); ¹H NMR (CDCl₃) δ 7.49-7.11 (m, 41H, Ph, NH), 5.92-5.82 (m, 1H, CH=CH₂), 5.50 (dd, $J_{2,3}$ = 2.9 Hz, $J_{1,2}$ = 1.9 Hz, 1H, H-2_B), 5.29–5.24 (m, J_{trans} = 17.3 Hz, 1H, CH=CH₂), 5.19–5.15 (m, J_{cis} = 10.4 Hz, 1H, CH= CH_2), 5.11 (bs, 1H, H-1_c), 5.00 (br s, 1H, H-1_c), 4.97 (d, $J_{1,2} = 3.7$ Hz, 1H, H-1_E), 4.91–4.86 (m, 2H, H_{Bn}), 4.81 (d, J =10.8 Hz, 1H, H_{Bn}), 4.75–4.67 (m, 6H, H-1_D, H_{Bn}), 4.63–4.45 (m, 8H, H_{Rn}), 4.34–4.29 (m, 1H, –OCH_{2All}), 4.08–4.01 (m, 3H, H-3_D, H-5_E, -OCH_{2All}), 3.94–3.78 (m, 11H, H-2_C, H-2_D, H-3_B, H-3_E, H-5_B, H-5_C, $H-5_{D}$, $H-6a_{D}$, $H-6b_{D}$, $H-6a_{E}$, $H-6b_{E}$), 3.72 (pt, J = 5.9 Hz, 1H, $H-4_{D}$), 3.66–3.63 (m, 2H, H-3_C, OH), 3.60–3.54 (m, 2H, H-2_E, H-4_E), 3.39 $(pt, J = 9.4 Hz, 1H, H-4_B), 3.29 (pt, J = 9.2 Hz, 1H, H-4_B), 2.75-2.67$ (m, 4H, 2 × CH_{2Lev}), 2.16 (s, 3H, CH_{3Lev}), 1.32 (d, $J_{5,6} = 6.1$ Hz, 3H, H-6_C), 1.28 (d, $J_{5,6} = 6.2$ Hz, 3H, H-6_B); ¹³C NMR (CDCl₃) δ 206.5 (C_{Lev}), 171.9 (C_{Lev}), 161.8 (NHCO), 138.8, 138.6, 138.3, 138.2, 138.1, 138.0, 137.8, 137.3 (8C_{quat}, Ph), 133.7 (CH=CH₂), 128.6, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7 (40C, Ph), 117.8 $(CH=CH_2)$, 99.8 $(C-1_B)$, 99.0 $(C-1_E)$, 98.3 $(C-1_D)$, 98.0 $(C-1_C)$, 92.4 (CCl_3) , 85.4 $(C-4_C)$, 81.8 $(C-3_E)$, 80.1, 80.0 $(2C, C-2_E, C-4_B)$, 77.9 $(2C, C-2_C, C-3_B), 77.8 (C-4_E), 76.3 (C-4_D), 75.6, 75.5, 75.2 (3C, C_{Bn}),$ 74.4 (C-3_D), 74.1 (C-5_D), 73.8, 73.7, 73.6 (4C, C_{Bn}), 71.8 (C_{Bn}), 71.3 $(C-5_E)$, 69.9 (OCH_{2All}) , 69.8 $(C-3_C)$, 69.6 $(C-6_D)$, 69.1 $(C-2_B)$, 68.6 $(C-6_E)$, 68.5 $(C-5_B)$, 67.8 $(C-5_C)$, 53.7 $(C-2_D)$, 38.2 (CH_{2Lev}) , 30.0 (CH_{3Lev}), 28.3 (CH_{2Lev}), 18.1, 18.0 (2C, C-6_B, C-6_C); HRMS (ESI⁺) m/z calcd for $C_{90}H_{100}Cl_3NO_{21}Na [M + Na]^+$ 1658.5751, found 1658.5919.

 $(3,4-Di-O-benzyl-2-levulinyl-\alpha-L-rhamnopyranosyl)-(1\rightarrow 2)-(3,4-di-O-benzyl-\alpha-L-rhamnopyranosyl)-(1\rightarrow 3)-[2,3,4,6-tetra-O-benzyl-\alpha-D-glucopyranosyl)-(1\rightarrow 4)]-(2-O-acetyl-\alpha-L-rhamnopyranosyl)-(1\rightarrow 3)-4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido-\alpha/\beta-D-glucopyranosyl trichloroacetimidate (40). To a solution of hemiacetal 39 (2.24 g, 1.14 mmol) in anhyd DCE (6 mL) and under argon$

atmosphere was added DBU (51 µL, 0.34 mmol, 0.3 equiv). The reaction mixture was cooled to 0 °C, and then trichloroacetonitrile (570 µL, 5.68 mmol, 5.0 equiv) was added. After 40 min of stirring at 0 °C, the volatiles were partially evaporated at room temperature, and the residue was purified by column chromatography (toluene/EtOAc, 90:10 + 2% Et₃N) to give imidate 40 (2.36 g, 1.12 mmol, 97%) as a white foam (α/β ratio 9:1): $R_f = 0.56$ (toluene/EtOAc 8.6:1.4 + 2% Et₃N); ¹H NMR (CDCl₃) $\delta(\vec{\alpha})$ 8.77 (s, 1H, C=NH), 7.37–7.13 (m, 50H, Ph), 6.88 (d, $J_{\rm NH,2}$ = 9.0 Hz, NH), 6.43 (d, $J_{1.2}$ = 2.9 Hz, 1H, H- $1_{\rm D}$), 5.56 (bs, 1H, H- $2_{\rm A}$), 5.19 (d, $J_{1,2}$ = 3.2 Hz, 1H, H- $1_{\rm C}$), 5.12 (bs, 1H, H-2_C), 5.05 (bs, 1H, H-1_A), 4.97–4.36 (m, 24H, 20H_{Bn}, H-1_B, H- 1_{E} , H- 2_{B} , H- 2_{D}), 4.20–3.37 (m, 20H, H- 2_{E} , H- 3_{A} , H- 3_{B} , H- 3_{C} , H- 3_{D} , H-3_E, H-4_A, H-4_B, H-4_C, H-4_D, H-4_E, H-5_A, H-5_B, H-5_C, H-5_D, H-5_E, H-6a_D, H-6b_D, H-6a_E, H-6b_E), 2.68–2.53 (m, 4H, 2 × CH_{2Lev}), 2.11, 2.10 (bs, 6H, CH_{3Lev}, H_{Ac}), $\overline{1.30-1.18}$ (m, 9H, H-6_A, H-6_B, $\overline{H-6_C}$); ${}^{13}C$ NMR (partial, CDCl₃) δ 206.1 (C_{Lev}), 171.8 (C_{Lev}), 170.0 (C_{Ac}), 161.7 (NHCO), 160.4 (C=NH), 138.9, 138.8, 138.7, 138.4, 138.3, 138.2, 137.9, 137.6 (10 $C_{\rm quar}$ Ph), 128.6, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5 (50C, Ph), 99.4 (C-1_A), 97.1 (C-1_C), 94.8 (C-1_D), 92.3 (C(O)CCl₃), 90.9 (C(NH)CCl₃), 54.9 (C- $2_{\rm D}$), 38.2 (CH_{2Lev}), 29.9 (CH_{3Lev}), 28.2 (CH_{2Lev}), 21.1 (C_{Ac}), 18.8, 18.3, 18.1 (3C, C-6_A, C-6_B, C-6_C)

2-Azidoethyl (3,4-Di-O-benzyl-2-O-levulinyl- α -L-rhamnopyranosyl)- $(1 \rightarrow 2)$ -(3, 4-di-O-benzyl- α - ι -rhamnopyranosyl)- $(1 \rightarrow 3)$ -[2, 3, 4, 6tetra-O-benzyl- α -D-glucopyranosyl)- $(1 \rightarrow 4)$]- $(2-O-acetyl-\alpha-L-rham$ nopyranosyl)- $(1 \rightarrow 3)$ -4,6-di-O-benzyl-2-deoxy-2-trichloroacetami $do-\beta$ -D-glucopyranoside (43). A solution of donor 40 (1.20 g, 0.57 mmol) and bromoethanol (120 μ L, 1.69 mmol, 3.0 equiv) in anhyd DCE (11 mL) containing 4 Å MS (1.2 g) was stirred under argon for 5 min. After the mixture was cooled to 0 \degree C, TMSOTf (10 μ L, 55 μ mol, 0.1 equiv) was added. The reaction mixture was stirred for 25 min at this temperature, Et₃N (50 μ L) was added, and the mixture was filtered over a pad of Celite and concentrated to dryness. The crude residue was taken up under argon atmosphere in anhyd DMF (11 mL), and then NaI (427 mg, 2.85 mmol, 5.0 equiv) followed by NaN₃ (183 mg, 2.81 mmol, 4.9 equiv) were added. The reaction mixture was heated to 80 °C, stirred for 2 h, and then concentrated. The residue was dissolved in EtOAc (100 mL), washed with water (20 mL) and then brine (20 mL), and the aqueous layer was back-extracted with CH_2Cl_2 (20 mL). The combined organics were dried (Na₂SO₄), filtered, and concentrated. The residue was purified by column chromatography (toluene/EtOAc, 100:0 \rightarrow 80:20) to give azide 43 (909 mg, 0.45 mmol, 78%) as a white foam. Analytical data were as reported previously.

O-(3,4-Di-O-benzyl-2-O-levulinyl- α -L-rhamnopyranosyl)-(1 \rightarrow 2)- $(3,4-di-O-benzyl-\alpha-1-rhamnopyranosyl)-(1\rightarrow 3)-[2,3,4,6-tetra-O-ben$ $zyl-\alpha-D-glucopyranosyl)-(1\rightarrow 4)]-(2-O-acetyl-\alpha-L-rhamnopyranosyl) (1\rightarrow 3)$ - $\tilde{2}$ -trichloromethyl-(4,6-di-O-benzyl-1,2-dideoxy- α -D-glucopyrano)-[2,1-d]-2-oxazoline (45). A suspension of acceptor 42 (1.0 g, 517 µmol), donor 40 (1.43 g, 676 µmol, 1.3 equiv), and freshly activated 4 Å MS (350 mg) in anhyd DCE (5 mL) was stirred for 15 min under an argon atmosphere. The reaction mixture was heated to 40 °C, and then TMSOTf (5 μ L, 27 μ mol, 0.05 equiv) was added. After 20 min, TLC analysis showed full conversion of the donor into a slightly less polar compound. TMSOTf (5 µL, 27 µmol, 0.05 equiv) was added, the reaction mixture was stirred for 30 min, and then TMSOTf (5 μ L, 27 μ mol, 0.05 equiv) was added once more. After the mixture was stirred for another 1 h 30 at 40 °C, Et₃N (50 μ L) was added, and the reaction mixture was filtered over a pad of Celite and concentrated to dryness. The residue was purified by column chromatography (toluene/EtOAc, 95:5 \rightarrow 85:15) to elute first oxazoline 45 (178 mg, 91 μ mol, 18%) as a white amorphous solid and then decasaccharide 46 (1.32 g) slightly contaminated with trichloroacetamide 43. Oxazoline 45: $R_f = 0.55$ (toluene/EtOAc, 8.4:1.6); ¹H NMR (CDCl₃) δ 7.28–7.04 (m, 51H, Ph, NH), 6.29 (d, $J_{1,2} = 7.2$ Hz, H-1_D), 5.50 (dd, $J_{2,3} = 3.0$ Hz, $J_{1,2} = 1.9$ Hz, 1H, H-2_A), 5.02-4.98 (m, 3H, H-1_A, H-1_C, H-2_C), 4.88-4.83 (m, 5H, 3H_{Bn}, H-1_B, $H-1_{E}$), 4.76–4.27 (m, 20H, 17 H_{Bn} , $H-2_{D}$, $H-3_{D}$), 3.92–3.30 (m, 19H, H-2_E, H-3_A, H-3_B, H-3_C, H-3_E, H-4_A, H-4_B, H-4_C, H-4_D, H-4_E, H-5_A, H-5_B, H-5_C, H-5_D, H-5_E, H-6a_D, H-6b_D, H-6a_E, H-6b_E), 2.59–2.43 (m, 4H, 2 × CH_{2Lev}), 2.05 (s, 3H, H_{Ac}), 2.00 (s, 3H, CH_{3Lev}), 1.28,

1.24, 1.13 (d, $J_{5,6} = 6.2$ Hz, 9H, H- 6_A , H- 6_B , H- 6_C); ¹³C NMR (partial, CDCl₃) δ 206.0 (C_{Lev}), 171.8 (C_{Lev}), 170.4 (C_{Ac}), 162.9 (C=N), 138.7, 138.6, 138.5, 138.4, 138.3, 138.2, 137.9, 137.5 (10C_{quat} Ph), 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.6, 127.5, 127.4, 127.3 (50C, Ph), 104.2 (C-1_D), 101.0 (C-1_B), 99.3 (C-1_A), 98.3 (C-1_E), 96.8 (C-1_C), 86.4 (CCl₃), 66.0 (C-2_D), 38.1 (CH_{2Lev}), 29.8 (CH_{3Lev}), 28.2 (CH_{2Lev}), 21.2 (C_{Ac}), 18.6, 18.5, 18.1 (3C, C- 6_A , C- 6_B , C- 6_C); HRMS (ESI⁺) m/z calcd for C₁₀₉H₁₁₈Cl₃NO₂₅Na [M + Na]⁺ 1968.6957, found 1968.7250.

2-Azidoethyl (3,4-Di-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 2)-(3,4di-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl)-(1 \rightarrow 4)]-(α -L-rhamnopyranosyl)-(1 \rightarrow 3)-(4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido- β -D-glucopyranosyl)-(1 \rightarrow 2)-(3,4-di-O-benzyl- α - ι -rhamnopyranosyl)-(1 \rightarrow 2)-(3,4-di-O-benzyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-[2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl)- $(1 \rightarrow 4)$]- $(\alpha$ -L-rhamnopyranosyl)- $(1 \rightarrow 3)$ -(4, 6-di-O-benzyl-2deoxy-2-trichloroacetamido- β -D-glucopyranoside (47). To a solution of fully protected decasaccharide 46 (244 mg, 62.8 μ mol) in DCM/MeOH (1:3, 4.0 mL) was added methanolic MeONa (25 wt %, 72 μ L, 0.32 mmol, 5.1 equiv). The reaction mixture was heated to 50 °C and stirred for 15 h, and then more methanolic MeONa (25 wt %, 43 μ L, 0.19 mmol, 3.0 equiv) was added, and the reaction mixture was heated to 60 °C. After being stirred for 6 h, the reaction mixture was neutralized by addition of Dowex 50Wx8-200 (H⁺), filtered over a pad of Celite, and concentrated. Column chromatography of the residue (toluene/EtOAc, 90:10 \rightarrow 84:16) afforded triol 47 (166 mg, 44.8 μ mol, 71%) as a white amorphous solid. Decasaccharide 47: $R_f = 0.32$ (toluene/EtOAc, 4:1); ¹H NMR (CDCl₃) δ 7.38–6.94 (m, 102H, Ph, NH),5.18–4.12 (m, 54H, 40H_{Bn}, H-1_A, H-1_A', H-1_B, H-1_B', H-1_C, H- $1_{C}'$, H- 1_{D} , H- $1_{D}'$, H- 1_{E} , H- $1_{E}'$, H- 2_{C} , H- $2_{C}'$, H- 3_{D} , H- $3_{D}'$), 4.01–3.28 (m, 46H, H-2_B, H-2_B', H-2_D, H-2_D', H-2_E, H-2_E', H-3_A, H-3_A', H-3_B, $H-3_{B}', H-3_{C}, H-3_{C}', H-3_{E}, H-3_{E}', H-4_{A}, H-4_{A}', H-4_{B}, H-4_{B}', H-4_{C}, H-4_{$ $4_{C}'$, $H-4_{D}$, $H-4_{D}'$, $H-4_{E}$, $H-4_{E}'$, $H-5_{A}$, $H-5_{A}'$, $H-5_{B}$, $H-5_{B}'$, $H-5_{C}$, $H-5_{C}'$, H-5_D, H-5_D', H-5_E, H-5_E', H-6a_D, H-6a_D', H-6b_D, H-6b_D', H-6a_E, H- $6a_{E^{'}},\,H\text{-}6b_{E^{'}},\,H\text{-}6b_{E^{'}},\,-\text{OCH}_{2}\text{CH}_{2}\text{N}_{3}),\,1.32-1.07\,\,(\text{m},\,18\text{H},\,H\text{-}6_{A},\,H\text{-}6_{A^{'}},\,H\text{-}6_{B},\,H\text{-}6_{B^{'}},\,H\text{-}6_{C},\,H\text{-}6_{C^{'}});\,^{13}\text{C}\,\,\text{NMR}\,\,(\text{partial},\,\text{CDCl}_{3})\,\,\delta\,\,162.0$ (NHCO), 161.9 (NHCO), 139.0, 138.8, 138.7, 138.6, 138.5, 138.4, 138.2, 138.0, 137.8, 137.5 (20C_{quat}, Ph), 128.9, 128.6, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.3 (100C, Ph), 92.6 (CCl₃), 92.5 (CCl₃), 50.9 (CH₂N₃), 18.6, 18.5, 18.4, 18.3, 18.2 (6C, C-6_A, C-6_A', C-6_B, C-6_B', C-6_C, C-6_C'); HRMS (ESI⁺) m/z calcd for $C_{206}H_{229}Cl_6N_6O_{45}$ [M + NH₄]⁺ 3717.4026, found 3716.8455; m/z calcd for $C_{206}H_{233}Cl_6N_7O_{45}$ [M + 2NH₄]²⁺ 1867.2145, found 1867.2684.

2-Aminoethyl α -L-Rhamnopyranosyl-(1 \rightarrow 2)- α -L-rhamnopyranosyl)- $(1 \rightarrow 3)$ - $[\alpha$ -D-qlucopyranosyl)- $(1 \rightarrow 4)$]- α -L-rhamnopyranosyl- $(1 \rightarrow 4)$ 3)-2-acetamido-2-deoxy- β -D-glucopyranosyl- $(1 \rightarrow 2)$ - α -L-rhamnopyranosyl- $(1 \rightarrow 2)$ - α - ι -rhamnopyranosyl- $(1 \rightarrow 3)$ - $[\alpha$ -D-glucopyranosyl)- $(1 \rightarrow 4)$]- α - ι -rhamnopyranosyl- $(1 \rightarrow 3)$ -2-acetamido-2-deoxy- β -Dglucopyranoside (5). Triol 47 (24 mg, 6.5 μ mol) in solution in t-BuOH/CH₂Cl₂/H₂O (4:7:1, 4.0 mL) was treated with Pd(OH)₂/C (24 mg), and the suspension was stirred an hydrogen atmosphere for 3 days. More $Pd(OH)_2$ (5.0 mg), K_2HPO_4 (3.8 mg), and H_2O (1.0 mL) were added, and stirring went on for an additional 24 h. Once more, $Pd(OH)_2/C$ (3.0 mg) and H_2O (1.0 mL) were added. After 24 h, an HPLC control indicated reaction completion. The suspension was filtered through a pad of Celite, and the filtrate was concentrated. RP-HPLC purification of the residue (5 μ m C18, 100 Å, 10 × 250 mm column) eluting with CH₃CN/0.08% aq TFA (0 \rightarrow 15% over 20 min at a flow rate of 5.5 mL.min⁻¹) gave the target decasaccharide 5 (6.3 mg, 58%) as a white powder following repeated freeze-drying. Analytical RP-HPLC (5 μ m, C18 100 Å, 4.6 × 150 mm, 215 nm) for decasaccharide 5 eluting with CH₃CN/0.08% aq TFA ($0 \rightarrow 15\%$ over 20 min at a flow rate of 1.0 mL.min⁻¹) indicated $t_{\rm R}$ = 4.76 min: ¹H NMR (D₂O, partial) δ 5.26 (br s, 2H, H-1_E, H-1_E'), 5.20, 5.13, 5.09, 5.04, 4.90, 4.88 (6s, 6H, H-1_A, H-1_A', H-1_B, H-1_B', H-1_C, H-1_C'), 4.78 (overlapped with D_2O , 1H, H-1_D'), 4.65 (d, $J_{1,2} = 8.5$ Hz, 1H, H-1_D), 4.26-3.37 (m, 50H), 3.34-3.24 (m, 2H, CH₂NH₂), 2.13 (s, 6H, H_{Ac}), 1.42–1.35 (m, 18H, H- 6_A , H- $6_A'$, H- 6_B , H- $6_B'$, H- 6_C , H- $6_C'$); ¹³C NMR (partial, D₂O) δ 177.1 (NHCO), 177.0 (NHCO), 104.9 (C- $1_{D}'$), 103.1 (C- 1_{D}), 100.1 (2C, C- 1_{E} , C- $1_{E}'$), 68.3 (OCH₂), 63.3 (C-

 $6_{\rm D},$ C-6_D', C-6_E, C-6_E'), 58.3, 57.7 (2C, C-2_D, C-2_D'), 42.1 (CH₂NH₂), 25.0, 24.9 (2C, NHAc), 20.5, 19.5, 19.3, 19.2 (6C, C-6_A, C-6_A', C-6_B, C-6_B', C-6_C, C-6_C'); HRMS (ESI⁺) *m/z* calcd for C₆₆H₁₁₃N₃O₄₅ [M + H]⁺ 1668.6725, found 1668.6951.Other analytical data were as described.⁵¹

Allyl (2,3-O-Isopropylidene- α - ι -rhamnopyranosyl)-(1 \rightarrow 3)-2deoxy-4,6-O-isopropylidene-2-trichloroacetamido- β -D-glucopyranoside (48). To a solution of disaccharide 1 (512 mg, 1.0 mmol) in anhyd DMF/acetone (1:1 v/v, 10 mL) stirred at 0 °C under an argon atmosphere were added CSA (48 mg, 0.21 mmol, 0.2 equiv) and 2methoxypropene (144 µL, 1.50 mmol, 1.5 equiv). After 1 h at this temperature, DMP (184 μ L, 1.50 mmol, 1.5 equiv) was added, and the reaction mixture was allowed to reach rt. After 15 h, more CSA (47 mg, 0.21 mmol, 0.2 equiv) and DMP (184 µL, 1.50 mmol, 1.5 equiv) were added. The reaction mixture was stirred for 20 h, then Et₂N (150 μ L, 1.10 mmol, 1.1 equiv) was added. Volatiles were removed under vacuum, and the residue was purified by column chromatography (cHex/EtOAc 70:30 \rightarrow 40:60) to give di-O-isopropylidene 48 (441 mg, 0.75 mmol, 75%) as a white amorphous solid: $R_f = 0.21$ (cHex/ EtOAc 3:2); $[\alpha]_{D}^{24} = -40$ (c 1.0; MeOH); ¹H NMR (MeOD) δ 5.91-5.81 (m, 1H, CH=CH₂), 5.29-5.23 (m, J_{trans} = 17.2 Hz, 1H, CH=CH₂), 5.15-5.12 (m, J_{cis} = 10.5 Hz, 1H, CH=CH₂), 5.07 (s, 1H, H-1_C), 4.65 (bd, $J_{1,2}$ = 8.3 Hz, 1H, H-1_D), 4.30–4.26 (m, 1H, -OCH_{2All}), 4.09-4.03 (m, 2H, -OCH_{2All}, H-2_C), 3.92-3.80 (m, 6H, $H-2_{D}$, $H-3_{D}$, $H-6a_{D}$, $H-6b_{D}$, $H-3_{C}$, $H-5_{C}$), 3.67 (m, $J_{4.5} = 9.3$ Hz, 1H, H- $4_{\rm D}$), 3.35–3.29 (m, 1H, H- $5_{\rm D}$), 3.20 (dd, $J_{4.5}$ = 10.2 Hz, $J_{3.4}$ = 7.7 Hz, 1H, H-4_C), 1.52 (s, 3H, H_{iPr}), 1.44 (s, 3H, H_{iPr}), 1.40 (s, 3H, H_{iPr}), 1.26 (s, 3H, H_{iPr}), 1.18 (d, $J_{5,6}$ = 6.2 Hz, 3H, H-6_C); ¹³C NMR (MeOD) δ 164.4 (NHCO), 135.0 (CH=CH₂), 117.5 (CH=CH₂), 110.2 (C_{iPr-C}), 101.6 (C-1_D), 100.9 (C_{iPr-D}), 99.3 (C-1_C), 94.0 (CCl₃), 79.6 (C-3_C), 78.2 (C-3_D), 77.2 (C-2_C), 75.6 (C-4_C), 74.2 (C-4_D), 71.3 $(-OCH_{2All})$, 68.7 (C-5_D), 67.1 (C-5_C), 63.2 (C-6_D), 59.5 (C-2_D), 29.7, 28.4, 26.6, 19.4 (4C, C_{iPr}), 18.0 (C-6_C); HRMS (ESI⁺) m/z calcd for $C_{23}H_{34}Cl_3NO_{10}Na [M + Na]^+ 612.1146$, found 612.1105.

Allyl (2,3-O-Isopropylidene-4-O-methyl- α -L-rhamnopyranosyl)- $(1\rightarrow 3)$ -2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido- β -D-glucopyranoside (49). To a solution of alcohol 48 (299 mg, 0.51 mmol) in anhyd THF (8 mL) stirred at 0 °C under an argon atmosphere was added NaH (60% in mineral oil, 60 mg, 1.50 mmol, 3.0 equiv). After 15 min, MeI (95 μ L, 1.53 mmol, 3.0 equiv) was added, and the reaction mixture was allowed to warm to rt. After 3 h of stirring, the solution was cooled to 0 $^\circ\text{C}$, MeOH (8 mL) was slowly added, and the volatiles were evaporated. The residue was purified by column chromatography (cHex/EtOAc, 75:25 \rightarrow 50:50) to give the methyl ether 49 (275 mg, 0.45 mmol, 89%) as a white amorphous solid: $R_f =$ 0.28 (cHex/EtOAc 7:3); $[\alpha]^{24}_{D} = -45$ (c 1.0; CHCl₃); ¹H NMR (CDCl₃) δ 6.66 (d, $J_{NH,2} = 8.7$ Hz, 1H, NH), 5.88–5.78 (m, 1H, CH=CH₂), 5.29–5.24 (m, J_{trans} = 17.3 Hz, 1H, CH=CH₂), 5.21– 5.17 (m, $J_{cis} = 10.5$ Hz, 1H, CH=CH₂), 5.04 (bs, 1H, H-1_C), 4.73 (d, $J_{1,2} = 8.5$ Hz, 1H, H-1_D), 4.35–4.29 (m, 1H, –OCH_{2All}), 4.10–4.02 (m, 4H, $-OCH_{2All}$, H-2_C, H-3_C, H-3_D), 3.94 (dd, $J_{6a,6b} = 10.8$ Hz, $J_{5,6a}$ = 5.4 Hz, 1H, H-6 a_D), 3.86–3.73 (m, 3H, H-2 $_D$, H-6 b_D , H-5 $_C$), 3.63 $(pt, J = 9.2 Hz, 1H, H-4_D), 3.52 (s, 3H, -OCH_3), 3.37-3.31 (m, 1H, 1H)$ H-5_D), 2.92 (dd, $J_{4,5}$ = 10.1 Hz, $J_{3,4}$ = 7.0 Hz, 1H, H-4_C), 1.49 (s, 3H, H_{iPr}), 1.48 (s, 3H, H_{iPr}), 1.41 (s, 3H, H_{iPr}), 1.28 (s, 3H, H_{iPr}), 1.22 (d, $J_{56} = 6.2$ Hz, 3H, H-6_C); ¹³C NMR (CDCl₃) δ 162.1 (NHCO), 133.3 $(CH=CH_2)$, 118.4 $(CH=CH_2)$, 109.1 (C_{iPr-C}) , 99.9 (C_{iPr-D}) , 99.3 (C-1_D), 98.2 (C-1_C), 92.5 (CCl₃), 83.7 (C-4_C), 78.2 (C-2_C), 76.1, 76.0 $(C-3_{C}, C-3_{D})$, 72.9 $(C-4_{D})$, 70.5 $(-OCH_{2All})$, 67.7 $(C-5_{D})$, 65.2 $(C-3_{D})$ 5_C), 62.2 (C-6_D), 59.8 (-OCH₃), 59.1 (C-2_D), 29.2, 28.2, 26.4, 19.2 (4C, C_{iPr}), 17.9 (C-6_C); HRMS (ESI⁺) m/z calcd for $C_{24}H_{36}Cl_3NO_{10}Na [M + Na]^+ 626.1302$, found 626.1290.

Allyl (4-O-Methyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2-deoxy-2-trichloroacetamido- β -D-glucopyranoside (6). To a solution of fully protected disaccharide 49 (106 mg, 175 μ mol) in CH₂Cl₂ (2 mL) was added TFA (50% aq, 2 mL). The biphasic mixture was vigorously stirred for 35 min and then repeatedly coevaporated with toluene and cyclohexane. The residue was purified by column chromatography (EtOAc) to give tetraol 6 (75 mg, 143 μ mol, 82%) as a white amorphous solid: $R_f = 0.17$ (EtOAc); $[\alpha]^{24}_{\rm D} = -54$ (c 1.0; MeOH); ¹H NMR (D₂O) δ 6.03–5.93 (m, 1H, CH=CH₂), 5.42–5.36 (m, $J_{\text{trans}} = 17.3$ Hz, 1H, CH=CH₂), 5.35–5.31 (m, $J_{\text{cis}} = 10.4$ Hz, 1H, CH=CH₂), 4.94 (d, $J_{1,2} = 1.7$ Hz, 1H, H-1_C), 4.82 (d, $J_{1,2} = 8.5$ Hz, 1H, H-1_D), 4.45–4.40 (m, 1H, –OCH_{2AII}), 4.28–4.23 (m, 1H, –OCH_{2AII}), 4.04 (dq, $J_{4,5} = 9.8$ Hz, 1H, H-5_C), 4.01 (dd, $J_{6a,6b} = 12.4$ Hz, $J_{5,6a} = 2.2$ Hz, 1H, H-6a_D), 3.95–3.81 (m, 5H, H-6b_D, H-2_D, H-3_D), H-2_C; H-3_C), 3.61 (s, 3H, –OCH₃), 3.66–3.54 (m, 2H, H-5_D, H-4_D), 3.25 (pt, $J_{3,4} = 9.7$ Hz, 1H, H-4_C), 1.33 (d, $J_{5,6} = 6.2$ Hz, 3H, H-6_C); ¹³C NMR (D₂O) δ 164.8 (NHCO), 133.1 (CH=CH₂), 118.8 (CH=CH₂), 101.1 (C-1_C), 99.1 (C-1_D), 91.6 (CCl₃), 82.2 (C-4_C), 80.6 (C-3_D), 76.1 (C-5_D), 70.9 (–OCH_{2AII}), 70.8 (C-2_C), 70.1 (C-3_C), 68.7 (C-4_D), 68.0 (C-5_C), 60.8 (C-6_D), 60.0 (–OCH₃), 57.4 (C-2_D), 16.7 (C-6_C); HRMS (ESI⁺) *m*/*z* calcd for C₁₈H₂₈Cl₃NO₁₀Na [M + Na]⁺ 546.0676, found 546.0681.

Allyl (2,3-O-Isopropylidene- α - ι -rhamnopyranos-4-ulosyl)-(1 \rightarrow 3)-2-deoxy-4,6-O-isopropylidene-2-trichloroacetamido- β -D-glucopyranoside (50). A solution of DMSO (301 μ L, 4.23 mmol, 5.0 equiv) in CH₂Cl₂ (1.0 mL) was added to a stirred solution of oxalyl chloride (179 µL, 2.12 mmol, 2.5 equiv) in CH₂Cl₂ (10 mL) at -78 °C under an argon atmosphere. After 30 min, a solution of alcohol 48 (500 mg, 0.85 mmol) in CH_2Cl_2 (2.0 mL) was added at -78 °C, and the reaction was stirred at this temperature for a further 45 min. After this time, Et₃N (850 μ L, 6.09 mmol, 7.2 equiv) was added, and the reaction was warmed to room temperature and diluted with $\mbox{CH}_2\mbox{Cl}_2$ (50 mL). The combined organics were successively washed with a saturated aqueous solution of NaHCO₃ (20 mL) and brine (20 mL) before being dried (Na₂SO₄) and concentrated to a pale yellow solid, which was purified by column chromatography (CH₂Cl₂/Me₂CO 9:1 \rightarrow 8:2) to give ketone 50 (416 mg, 0.71 mmol, 84%) as a white amorphous solid: $R_f = 0.38$ (CH₂Cl₂/Me₂CO 4:1); ¹H NMR (DMSO d_6) δ 9.18 (d, $J_{\rm NH,2}$ = 9.2 Hz, 1H, NH), 5.88–5.75 (m, 1H, CH= CH₂), 5.28–5.20 (m, J_{trans} = 17.3 Hz, 1H, CH=CH₂), 5.15–5.09 (m, $J_{cis} = 10.7$ Hz, 1H, CH=CH₂), 5.07 (bs, 1H, H-1_C), 4.70 (q, $J_{5.6} = 6.5$ Hz, 1H, H-5_C), 4.64 (d, $J_{1,2}$ = 8.2 Hz, 1H, H-1_D), 4.62 (d, $J_{2,3}$ = 5.5 Hz, 1H, H-3_C), 4.25–4.15 (m, 2H, –OCH_{2All}, H-2_C), 4.06–3.98 (m, 1H, $-OCH_{2AII}$), 3.99 (pt, J = 9.5 Hz, H-3_D), 3.92-3.82 (m, 2H, H-2_D, H- $6a_D$), 3.77 (pt, J = 10.4 Hz, 1H, H- $6b_D$) 3.70 (pt, J = 9.3 Hz, 1H, H-4_D), 3.31–3.22 (m, 1H, H-5_D), 1.46 (s, 3H, H_{iPr}), 1.31 (s, 3H, H_{iPr}), 1.27 (s, 3H, H_{iPr}), 1.20 (s, 3H, H_{iPr}), 1.13 (d, $J_{5,6}$ = 6.5 Hz, 3H, H-6_C) ppm; ¹³C NMR (DMSO-*d*₆) δ 204.7 (C-4_C), 161.8 (NHCO), 134.1 (CH=CH₂), 116.6 (CH=CH₂), 109.7 (C_{iPr-C}), 100.1 (C-1_D), 99.2 (C_{iPr-D}), 97.1 (C-1_C), 92.9 (CCl₃), 78.9 (C-2_C), 77.1 (C-3_D), 75.6 (C- $3_{\rm C}$), 72.1 (C- $4_{\rm D}$), 69.5 (-OCH_{2AII}), 68.3 (C- $5_{\rm C}$), 65.9 (C- $5_{\rm D}$), 61.4 (C-6_D), 57.5 (C-2_D), 28.9, 26.7, 25.5, 19.0 (4C, C_{iPr}), 14.6 (C-6_C); HRMS (ESI⁺) m/z calcd for C₂₃H₃₂Cl₃NO₁₀Na [M + Na]⁺ 702.0735, found 702.0714.

Allyl (α -L-Rhamnopyranos-4-ulosyl)-(1 \rightarrow 3)-2-deoxy-2-trichloroacetamido- β -D-glucopyranoside (7). A solution of fully protected disaccharide 50 (1.0 g, 1.70 mmol) in AcOH (80% aq, 34 mL) was stirred at 80 °C overnight and then repeatedly coevaporated with a 2:1 mixture of cyclohexane and toluene. The residue was purified by column chromatography (CH₂Cl₂/MeOH 9:1 \rightarrow 8:2) to give tetraol 7 (600 mg, 1.18 mmol, 69%) as a white amorphous solid: $R_f = 0.16$ $(CH_2Cl_2/MeOH 4:1)$; ¹H NMR (DMSO- d_6 + D₂O) δ 5.87–5.75 (m, 1H, CH=CH₂), 5.25-5.17 (m, $J_{\text{trans}} = 17.3$ Hz, 1H, CH=CH₂), 5.12–5.07 (m, J_{cis} = 10.5 Hz, 1H, CH=CH₂), 4.91 (d, $J_{1,2}$ = 2.1 Hz, 1H, H-1_C), 4.73 (qd, $J_{5,6}$ = 6.5 Hz, $J_{3,5}$ = 0.6 Hz, 1H, H-5_C), 4.54 (d, $J_{1,2}$ = 8.4 Hz, 1H, H-1_D), 4.41 (dd, $J_{2,3}$ = 3.5 Hz, $J_{3,5}$ = 0.6 Hz, 1H, H-3_C), 4.26-4.19 (m, 1H, -OCH_{2All}), 4.04-3.97 (m, 1H, -OCH_{2All}), 3.94 (dd, $J_{2,3}$ = 3.5 Hz, $J_{1,2}$ = 2.1 Hz, 1H, H-2_C), 3.86 (dd, $J_{2,3}$ = 10.3 Hz, $J_{3,4}$ = 8.8 Hz, 1H, H-3_D), 3.73–3.61 (m, 2H, H-6a_D, H-2_D), 3.52 (dd, $J_{6a,6b}$ = 12.0 Hz, $J_{5,6b}$ = 5.6 Hz, 1H, H-6b_D), 3.30 (dd, $J_{4,5}$ = 9.9 Hz, $J_{3,4}$ 8.8 Hz, 1H, H-4_D), 3.22 (ddd, $J_{4,5} = 9.9$ Hz, $J_{5,6b} = 5.6$ Hz, $J_{5,6a} = 1.8$ Hz, 1H, H-5_D), 1.06 (d, $J_{5,6}$ = 6.5 Hz, 3H, H-6_C) ppm; ¹³C NMR (DMSO d_6) δ 207.9 (C-4_C), 161.6 (NHCO), 134.4 (CH=CH₂), 116.3 (CH= CH₂), 99.9 (C-1_C), 99.4 (C-1_D), 93.0 (CCl₃), 79.3 (C-3_D), 76.8 (C- $5_{\rm D}$), 75.0 (C-2_C), 73.3 (C-3_C), 70.3 (C-5_C), 69.0 (-OCH_{2All}), 68.9 (C- $4_{\rm D}$), 60.7 (C- $6_{\rm D}$), 57.4 (C- $2_{\rm D}$), 13.8 (C- $6_{\rm C}$); HRMS (ESI⁺) m/z calcd for $C_{17}H_{24}Cl_3NO_{10}Na [M + Na]^+$ 530.0364, found 530.0280.

Allyl (2,3,4-Tri-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-4,6-di-Oacetyl-2-deoxy-2-trichloroacetamido- β -D-glucopyranoside (51). To a solution of disaccharide 1 (1.01 g, 1.97 mmol) in anhyd Py (30 mL) under an argon atmosphere was added DMAP (25 mg, 0.20 mmol, 0.1 equiv). The reaction mixture was cooled to 0 °C acetic anhydride (20 mL, 212 mmol, 107 equiv) was added, and the reaction mixture was allowed to warm to rt. After 14 h of stirring, the reaction mixture was cooled to 0 °C. The reaction was quenched by the slow addition of MeOH (20 mL), and the mixture was concentrated then coevaporated twice with toluene. The residue was purified by column chromatography (cHex/EtOAc, 50:50) to give the fully protected disaccharide 51 (1.34 g, 1.86 mmol, 94%) as a white amorphous solid: $R_f = 0.45$ (cHex/EtOAc 1:1); $[\alpha]^{24}_{D} = -2$ (c 1.0; CHCl₃); ¹H NMR (CDCl₃) δ 7.16 (d, $J_{\rm NH,2}$ = 6.9 Hz, 1H, NH), 5.91–5.81 (m, 1H, CH=CH₂), 5.29-5.24 (m, $J_{\text{trans}} = 17.3$ Hz, 1H, CH=CH₂), 5.22-5.17 (m, 3H, CH=CH₂, H-2_C, H-3_C), 5.09 (d, $J_{1,2}$ = 8.1 Hz, 1H, H-1_D), 5.11-4.98 (m, 2H, H-4_C, H-4_D), 4.83 (d, $J_{1,2}$ = 1.6 Hz, 1H, H-1_C), 4.53 (dd, $J_{2,3}$ = 10.0 Hz, $J_{3,4} = 8.6$ Hz, 1H, H-3_D), 4.36–4.31 (m, 1H, –OCH_{2All}), 4.23 (dd, $J_{6a,6b}$ = 12.3 Hz, $J_{5,6a}$ = 5.1 Hz, 1H, H-6a_D), 4.13-4.06 (m, $J_{5,6b}$ = 2.7 Hz, 2H, $-OCH_{2Alb}$, H-6b_D), 3.86 (dq, $J_{4,5} = 9.8$ Hz, 1H, H-5_C), 3.64 (ddd, $J_{4,5}$ = 7.9 Hz, 1H, H-5_D), 3.42–3.35 (m, 1H, H-2_D), 2.10 (s, 6H, H_{Ac}), 2.09, 2.03, 1.94 (3s, 9H, H_{Ac}), 1.16 (d, $J_{5,6}$ = 6.2 Hz, 1H, H- $6_{\rm C}$); ¹³C NMR (CDCl₃) δ 170.8, 170.1, 170.0, 169.9, 169.8 (5C, C_{Ac}), 162.5 (NHCO), 133.4 (CH=CH₂), 118.6 (CH=CH₂), 99.7 (C-1_c), 97.4 (C-1_D), 92.1 (CCl₃), 78.6 (C-3_D), 72.0 (C-5_D), 70.9 (-OCH_{2All}), 70.7 (C-4_C), 70.4 (C-4_D), 70.0 (C-2_C), 68.9 (C-3_C), 67.9 (C-5_C), 62.4 $(C-6_D)$, 59.1 $(C-2_D)$, 21.3 (C_{Ac}) , 21.0 (C_{Ac}) , 20.9 $(2C, C_{Ac})$, 20.8 (C_{Ac}) , 17.4 $(C-6_C)$; HRMS (ESI^+) m/z calcd for $C_{27}H_{36}Cl_3NO_{15}Na$ $[M + Na]^+$ 742.1048, found 742.0972.

2,3,4-Tri-O-acetyl- α - ι -rhamnopyranosyl-(1 \rightarrow 3)-4,6-di-O-acetyl-2deoxy-2-trichloroacetamido- α/β -D-glucopyranose (52). 1,5-Cyclooctadiene-bis(methyldiphenylphosphine)iridium hexafluorophosphate (63 mg, 74 μ mol, 0.03 equiv) was dissolved in anhyd THF (20 mL) under an argon atmosphere. Hydrogen was bubbled through the solution for 15 min, causing the color to change from red to yellow. The solution was degassed by complete evaporation of the solvent under vacuum. The activated iridium complex was dissolved under an argon atmosphere in anhyd THF (10 mL) and added to a solution of 51 (1.72 g, 2.39 mmol) in anhyd THF (30 mL). The reaction mixture was stirred for 4 h at rt, and then a solution of iodine (1.21 g, 4.77 mmol, 2.0 equiv) in THF/water (40 mL, 3:1 v/v) was added. After 16 h, the excess iodine was quenched by addition of a 10% aq sodium bisulfite solution (30 mL). The reaction mixture was concentrated under reduced pressure to remove THF, and the aqueous phase was extracted with CH_2Cl_2 (2 × 60 mL). The combined organics were washed with brine $(1 \times 20 \text{ mL})$, dried (Na₂SO₄), filtered, and concentrated to dryness. Column chromatography of the residue (cHex/EtOAc, 60:40 \rightarrow 30:70) afforded hemiacetal 52 (1.39 g, 2.04 mmol, 85%) as a pale yellow amorphous solid $(\alpha/\beta, 9:1)$. α : $R_f = 0.28$ (cHex/EtOAc 1:1); ¹H NMR (CDCl₃) δ 6.92 (d, $J_{\rm NH,2}$ = 9.1 Hz, 1H, NH), 5.35 (pt, J = 3.7 Hz, 1H, H-1_D), 5.23 (dd, $J_{3,4} = 10.0$ Hz, $J_{2,3} = 3.4$ Hz, 1H, H-3_C), 5.15–5.08 (m, 2H, H-4_D, H-2_C), 4.98 (pt, J = 9.9 Hz, 1H, H-4_C), 4.88 (d, $J_{1,2} = 1.8$ Hz, 1H, H-1_C), 4.30–4.24 (m, 1H, H-2_D), 4.19–4.05 (m, 4H, H-3_D, H-5_D, H-6a_D, H-6b_D), 3.90 (dq, $J_{4,5}$ = 9.9 Hz, 1H, H-5_C), 2.12, 2.11, 2.09, 2.01, 1.93 (5s, 15H, H_{Ac}), 1.16 (d, $J_{5,6}$ = 6.3 Hz, 1H, H-6_C); ¹³C NMR (CDCl₃) δ 171.1, 170.5, 170.2, 169.7, 169.4 (5C, C_{Ac}), 162.1 (NHCO), 99.4 (C-1_C), 92.4 (CCl₃), 91.2 (C-1_D), 78.5 (C-3_D), 71.2 (C-4_C), 70.7 (C-2_C), 69.9 (C-4_D), 68.4 (C-3_C), 68.0 (C-5_D), 67.7 (C-5_C), 62.2 (C-6_D), 54.7 $(C-2_D)$, 21.2 (C_{Ac}) , 21.0 (C_{Ac}) , 20.9 $(2C, C_{Ac})$, 20.7 (C_{Ac}) , 17.2 $(C-C_{Ac})$ $6_{\rm C}$; HRMS (ESI⁺) m/z calcd for $C_{24}H_{32}Cl_3NO_{15}Na$ [M + Na]⁺ 702.0735, found 702.0714.

Methyl (2,3,4-Tri-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-4,6-di-O-acetyl-2-deoxy-1-thio-2-trichloroacetamido- β -D-glucopyranoside (54) and O-(2,3,4-Tri-O-acetyl- α -L-rhamnopyranosyl)-(1 \rightarrow 3)-2-tri-chloromethyl-(4,6-di-O-acetyl-1,2-dideoxy- α -D-glucopyrano)-[2,1-d]-2-oxazoline (53). To a solution of hemiacetal 52 (668 mg, 0.98 mmol) in anhyd CH₂Cl₂ (10 mL) under an argon atmosphere were added Cs₂CO₃ (64 mg, 0.20 mmol, 0.2 equiv) and trichloroacetonitrile (490 μ L, 4.89 mmol, 5.0 equiv). The reaction mixture was stirred for

60 min, filtered on Celite, and concentrated. The residue was dissolved in CH₂Cl₂ (10 mL) under an argon atmosphere, and freshly activated MS were added (530 mg). The reaction mixture was cooled to -15°C, and then methyl trimethylsilyl sulfide (710 μ L, 5.00 mmol, 5.0 equiv) followed by TMSOTf (13 μ L, 0.05 mmol, 0.05 equiv) was added. The reaction mixture was stirred overnight while being allowed to slowly reach rt, and then Et_3N (20 μ L) was added. The mixture was filtered on Celite and concentrated, and then column chromatography of the residue (cHex/EtOAc, 90:10 \rightarrow 50:50) afforded first oxazoline 53 (324 mg, 0.49 mmol, 50%) and then the expected thioglycoside 54 (221 mg, 0.31 mmol, 31%), both as white amorphous solids. Oxazoline 53: $R_f = 0.51$ (cHex/EtOAc 1:1); $[\alpha]_{D}^{24} = -30$ (c 1.0; CHCl₃); ¹H NMR (CDCl₃) δ 6.37 (d, $J_{1,2}$ = 7.4 Hz, 1H, H-1_D), 5.25 (dd, $J_{3,4}$ = 10.1 Hz, $J_{2,3}$ = 3.4 Hz, 1H, H-3_C), 5.20 (dd, $J_{1,2}$ = 1.7 Hz, 1H, H-2_C), 5.09 (pt, $J_{4.5}$ = 9.9 Hz, 1H, H-4_C), 5.04–5.02 (m, $J_{4.5}$ = 8.3 Hz, 1H, H-4_D), 4.99 (d, 1H, H-1_C), 4.47–4.44 (m, $J_{2,3} = 2.7$ Hz, 1H, H-2_D), 4.35–4.34 (m, 1H, H-3_D), 4.28 (dd, $J_{6a,6b}$ = 12.2 Hz, $J_{5,6a}$ = 3.1 Hz, 1H, H-6a_D), 4.16 (dd, $J_{5.6b}$ = 6.0 Hz, 1H, H-6b_D), 4.09–4.02 (dq, 1H, H-5_C), 3.79 (ddd, 1H, H-5_D), 2.16, 2.11, 2.08, 2.05, 1.99 (5s, 15H, H_{Ac}), 1.24 (d, $J_{5,6}$ = 6.3 Hz, 1H, H-6_C); ¹³C NMR (CDCl₃) δ 170.7, 170.3, 170.0, 169.9, 169.7 (5C, C_{Ac}), 163.4 (C=N), 103.5 (C-1_D), 96.5 (C-1_C), 86.2 (CCl₃), 72.3 (C-3_D), 70.8 (C-4_C), 69.9 (C-2_C), 68.8 $(C-3_{C})$, 68.6, 68.5 (2C, C-4_C, C-5_D), 67.6 (C-5_C), 64.2 (C-2_D), 63.6 $(C-6_D)$, 21.0, 20.9, 20.8 (3C, C_{Ac}), 20.7 (2C, C_{Ac}), 17.4 (C-6_C); HRMS (ESI⁺) m/z calcd for C₂₄H₃₀Cl₃NO₁₄Na [M + Na]⁺ 684.0630, found 684.0669

Thioglycoside **54**: $R_f = 0.38$ (cHex/EtOAc 1:1); $[\alpha]^{24}_D = 0$ (*c* 1.0; CHCl₃); ¹H NMR (CDCl₃) δ 7.14 (d, $J_{NH,2} = 7.6$ Hz, 1H, NH), 5.20– 5.16 (m, 2H, H-2_C H-3_C), 5.07–4.97 (m, 3H, H-4_C, H-1_D, H-4_D), 4.85 (d, $J_{1,2} = 1.7$ Hz, 1H, H-1_C), 4.37 (t, J = 9.6 Hz, 1H, H-3_D), 4.20 (dd, $J_{6a,6b} = 12.4$ Hz, $J_{5,6a} = 5.2$ Hz, 1H, H-6a_D), 4.10 (dd, $J_{5,6b} = 2.6$ Hz, 1H, H-6b_D), 3.89–3.82 (dq, $J_{4,5} = 9.9$ Hz, 1H, H-5_C), 3.67–3.57 (m, 2H, H-2_D, H-5_D), 2.21 (s, 3H, SCH₃), 2.10, 2.09, 2.08, 2.01, 1.94 (5s, 15H, H_{Ac}), 1.15 (d, $J_{5,6} = 6.2$ Hz, 1H, H-6_C); ¹³C NMR (CDCl₃) δ 170.3, 170.1, 170.0, 169.9, 169.8 (5C, C_{Ac}), 162.2 (NHCO), 99.6 (C-1_C), 92.1 (CCl₃), 82.2 (C-1_D), 80.1 (C-3_D), 76.2 (C-5_D), 70.8 (3C, C-2_C, C-4_C, C-4_D), 68.8 (C-3_C), 67.9 (C-5_C), 62.6 (C-6_D), 57.5 (C-2_D), 21.2, 21.0, 20.9, 20.8, 20.7 (5C, C_{Ac}), 12.5 (S-CH₃); HRMS (ESI⁺) m/z calcd for C₂₅H₃₄Cl₃NO₁₄SNa [M + Na]⁺ 732.0663, found 732.0718.

Methyl α -L-Rhamnopyranosyl- $(1 \rightarrow 3)$ -2-deoxy-1-thio-2-trichloroacetamido- β -D-glucopyranoside (8). To a solution of fully protected thioglycoside 54 (269 mg, 0.38 mmol) in MeOH (5 mL) was added methanolic MeONa (25 wt %, 87 µL, 0.38 mmol, 1.0 equiv). The reaction mixture was stirred for 90 min, neutralized by addition of Dowex 50Wx8-200, filtered over a pad of Celite, and concentrated. Column chromatography of the residue (CH₂Cl₂/ MeOH, 90:10 \rightarrow 80:20) afforded pentaol 8 (174 mg, 0.35 mmol, 91%) as a white amorphous solid: $R_f = 0.30$ (CH₂Cl₂/MeOH 8.5:1.5); $[\alpha]^{24}_{D} = -61 (c 1.0; MeOH); {}^{1}H NMR (D_2O) \delta 4.98 (d, J_{1,2} = 1.7 Hz)$ 1H, H-1_C), 4.78 (overlapped with D_2O , 1H, H-1_D), 4.11–3.99 (m, 3H, $H-5_{C}$, $H-2_{D}$, $H-6a_{D}$), 3.91-3.78 (m, 4H, $H-2_{C}$, $H-3_{C}$, $H-3_{D}$, $H-6b_{D}$), 3.66 (dd, $J_{3,4}$ = 9.9 Hz, $J_{4,5}$ = 8.4 Hz, 1H, H-4_D), 3.62–3.59 (m, 1H, H- 5_D), 3.51 (pt, J = 9.7 Hz, 1H, H- 4_C), 2.28 (s, 3H, SCH₃), 1.31 (d, $J_{5,6} =$ 6.2 Hz, 1H, H-6_C); ¹³C NMR (D₂O) δ 167.2 (NHCO), 104.0 (C-1_C), 94.1 (CCl₃), 85.8 (C-1_D), 84.8 (C-3_D), 82.9 (C-5_D), 74.5 (C-4_C), 73.3(C-2_C), 73.0 (C-3_C), 71.6 (C-5_C), 71.2 (C-4_D), 63.5 (C-6_D), 58.5 $(C-2_D)$, 19.1 $(C-6_C)$, 14.2 $(S-CH_3)$; HRMS (ESI^+) m/z calcd for $C_{15}H_{24}Cl_3NO_9SNa [M + Na]^+ 522.0135$, found 522.0093.

Allyl (2,3,4-Tris-O-(tert-butyldimethylsilyl)- α -1-rhamnopyranosyl)-(1 \rightarrow 3)-4,6-bis-O-(tert-butyldimethylsilyl)-2-deoxy-2-trichloroacetamido- β -D-glucopyranoside (55). To a solution of disaccharide 1 (511 mg, 1.00 mmol) in dry Py (10 mL), under an argon atmosphere at 0 °C, was added *tert*-butyldimethylsilyl trifluoromethanesulfonate (2.3 mL, 10.0 mmol, 10.0 equiv) dropwise. The reaction mixture was heated to 60 °C for 15 h and then cooled to 0 °C. The reaction was quenched by addition of MeOH (10 mL). Volatiles were concentrated and coevaporated twice with toluene. Column chromatography of the residue (cHex/EtOAc, 100:0 \rightarrow 98:2) afforded the fully protected disaccharide 55 (930 mg, 0.86 mmol, 86%) as a colorless oil (rotameric mixture 3:2): $R_f = 0.78$ (cHex/EtOAc 90:10); $[\alpha]^{24}_D =$

Featured Article

-33 (c 1.0; CHCl_3); $^1\mathrm{H}$ NMR (CDCl_3) δ 7.76 (d, $J_{\mathrm{NH,2}}$ = 8.7 Hz, 0.6H, NH), 7.40 (d, J_{NH,2} = 8.8 Hz, 0.4H, NH), 5.89–5.83 (m, 1H, CH=CH₂), 5.29-5.14 (m, 2H, CH=CH₂), 4.78-4.75 (m, 1H, H-1_C), 4.72 (br s, 1H, H-1_D), 4.28–4.24 (m, 1H, –OCH_{2All}), 4.10–3.95 (m, 4H, -OCH_{2All}, H-2_D, H-4_D, H-6a_D), 3.88–3.54 (m, 6.6H, H-2_C, H-3_C, H-4_C, H-5_C, H-3_D, H-5_D, H-6b_D), 3.41 (br d, J = 5.0 Hz, 0.4H, H-4_C), 1.22 (br s, 3H, H-6_C), 0.93-0.88 (m, 45H, CH_{3(BuSi}), 0.17-0.06 (m, 30H, SiCH₃); ¹³C NMR (CDCl₃) δ 161.5 (NHCO major), 161.2 (NHCO minor), 134.1 (CH=CH₂), 117.7 (CH=CH₂ major), 117.4 (CH=CH₂ minor), 102.3 (C-1_C minor), 99.6 (C-1_C major), 98.0 (C-1_D minor), 97.4 (C-1_D major), 92.8 (CCl₃ minor), 92.6 (CCl₃ major), 79.9 (C-3_D major), 79.6 (C-3_D minor), 78.5 (C-4_C minor), 77.19 (C-4_C major), 76.7 (C-3_C minor), 74.1 (C-5_D major), 73.9 (C-5_D minor), 73.4, 73.2 (C-2_C major, C-3_C major), 71.9 (C-5_C major), 71.4, 71.3 (C-2_C minor, C-5_C minor), 69.6 (-OCH_{2All} major), 69.3 (-OCH_{2All} minor), 69.1 (C-4_D minor), 68.4 (C-4_D major), 64.0 (C-6_D major), 63.8 (C-6_D minor), 53.9 (C-2_D minor), 49.7 (C-2_D major), 27.1, 26.9, 26.5, 26.3, 26.2, 26.0, 25.9 (15C, CH_{3(BuSi}), 20.1 (C-6_C minor), 18.8 (C-6_C major), 18.6, 18.4, 18.3, 18.0 (5C, Si-C_{tBu}), -2.3, -3.3, -3.6, -3.7, -3.9, -4.2, -4.3, -4.4, -4.6, 4.8, -4.9, 5.1 (10C, Si-CH₃); HRMS (ESI⁺) m/z calcd for C₄₇H₉₆Cl₃NO₁₀Si₅Na [M + Na]⁺ 1102.4844, found 1102.4854.

 $(2,3,4-Tris-(O-tert-buty/dimethy/silyl)-\alpha-L-rhamnopyranosyl)-(1 \rightarrow$ 3)-4,6-bis-O-(tert-butyldimethylsilyl)-2-deoxy-2-trichloroacetamido- α/β -D-glucopyranose (56). 1,5-Cyclooctadiene-bis(methyldiphenylphosphine)iridium hexafluorophosphate (19 mg, 22 µmol, 0.03 equiv) was dissolved in anhyd THF (5 mL) under an argon atmosphere. Hydrogen was bubbled through the solution for 15 min, causing the color to change from red to yellow. The solution was degassed by complete evaporation of the solvent under vacuum. The activated iridium complex was dissolved under an argon atmosphere in anhyd THF (10 mL) and added to a solution of 55 (810 mg, 0.75 mmol) in anhyd THF (10 mL). The reaction mixture was stirred for 2 h 30 at rt, and then a solution of iodine (383 mg, 1.51 mmol, 2.0 equiv) in THF/ water (10 mL, 2:1 v/v) was added. After 60 min, the excess iodine was consumed by addition of 10% aq sodium bisulfite (8 mL). The reaction mixture was concentrated under reduced pressure to remove THF, and the aqueous phase was extracted with CH_2Cl_2 (3 × 30 mL). The combined organics were dried (Na₂SO₄), filtered, and concentrated to dryness. Column chromatography of the residue (cHex/EtOAc, 97:3 \rightarrow 90:10) afforded hemiacetal 56 (653 mg, 0.63 mmol, 84%) as a white amorphous solid (α/β ratio 2:1, rotameric mixture 7:3): $R_f = 0.30$ (cHex/EtOAc 9:1). α : ¹H NMR (CDCl₃) δ 7.72 (d, $J_{\rm NH,2}$ = 8.8 Hz, 0.7H, NH), 7.63 (d, $J_{\rm NH,2}$ = 8.4 Hz, 0.3H, NH), 5.22 (dd, $J_{1,OH}$ = 7.1 Hz, $J_{1,2}$ = 2.5 Hz, 0.7H, H-1_D), 4.82–4.81 (m, 1H, H-1_C), 4.23–3.56 (m, 9H, H-2_C, H-2_D, H-3_C, H-3_D, H-4_D, H-5_C, H-5_D, H-6a_D, H-6b_D), 3.46–3.42 (m, 1H, H-4_C), 3.17 (d, 0.7H, OH), 1.27– 1.21 (br s, 3H, H-6_C), 0.93-0.89 (m, 45H, CH_{3tBuSi}), 0.18-0.07 (m, 30H, SiCH₃). ¹³C NMR (partial, CDCl₃) δ 162.7 (NHCO major), 162.5 (NHCO minor), 102.1 (C-1_C major), 102.0 (C-1_C minor), 93.5 (CCl₃ minor), 92.7 (CCl₃ major), 89.0 (C-1_D major), 88.7 (C-1_D minor), 62.3 (C-6_D minor), 62.1 (C-6_D major), 53.1 (C-2_D major), 52.9 (C-2_D minor), 26.8, 26.5, 26.2, 26.1, 26.0, 25.9, 25.8 (15C, CH_{3tBuSi}), 20.1 (C-6_C), 18.9, 18.5, 18.3, 18.0 (5C, Si-C_{tBu}), -3.8, -3.9, -4.2, -4.3, -4.4, -4.5, -5.0, -5.2 (10C, Si-CH₃); HRMS (ESI⁺) m/z calcd for $C_{44}H_{92}Cl_3NO_{10}Si_5Na$ [M + Na]⁺ 1062.4531, found 1062.4498.

 α -1-Rhamnopyranosyl-(1 \rightarrow 3)-2-deoxy-2-trichloroacetamido- α / β -D-glucopyranose (9). Route 1. 1,5-Cyclooctadiene-bis-(methyldiphenylphosphine)iridium hexafluorophosphate (21 mg, 24 μ mol, 0.03 equiv) was dissolved in THF (10 mL) under an argon atmosphere. Hydrogen was bubbled through the solution for 20 min, causing the color to change from red to yellow. The solution was degassed by complete evaporation of the solvent under vacuum. The activated iridium complex was dissolved in THF (10 mL) under an argon atmosphere, and a solution of allyl glycoside **48** (499 mg, 845 μ mol) in THF (15 mL) was added. The reaction mixture was stirred for 75 min at rt, and then a solution of iodine (430 mg, 1.69 mmol, 2.0 equiv) in THF/water (15 mL, 4:1 v/v) was added. After 3 h, the excess iodine was quenched by addition of 10% aq sodium bisulfite (10 mL). The reaction mixture was concentrated under reduced pressure to remove THF, water (5 mL) was added, and the aqueous phase was extracted with CH₂Cl₂ (2 × 40 mL). The aqueous phase was concentrated and then suspended in EtOH. The residue was dissolved in AcOH/H₂O (1:1 v/v, 10 mL), and the reaction mixture was heated at 80 °C for 3 h. The volatiles were removed under vacuum and then coevaporated repeatedly with cyclohexane and toluene. Reversed-phase column chromatography of the residue (H₂O/MeOH 80:20) afforded lactol **9** (59 mg, 126 μ mol, 15%) as a white amorphous solid (α/β , 8:2).

Route 2. To a solution of hemiacetal 56 (202 mg, 194 μ mol) in anhyd THF (5 mL) under an argon atmosphere was added Et₃N·3HF (175 μ L, 975 μ mol, 5.0 equiv). The reaction mixture was stirred for 19 h, more Et₃N·3HF (70 μ L, 390 μ mol, 2.0 equiv) was added, and the reaction mixture was heated to 50 °C. After 6 h, Et₃N·3HF (105 μ L, 390 μ mol, 2.0 equiv) was added once more, and the reaction mixture was stirred at 50 °C for 20 h before being neutralized by addition of Et₃N (1 mL). Volatiles were removed under vacuum. Column chromatography of the residue (CH₂Cl₂/MeOH, 95:5 \rightarrow 75:25) followed by several freeze-dry cycles afforded the fully deprotected disaccharide 9 (65 mg, 138 μ mol, 70%) as a white amorphous solid $(\alpha/\beta, 7:3)$: $R_f = 0.39(\alpha), 0.24(\beta)$ (CH₂Cl₂/MeOH 4:1); ¹H NMR (D₂O) δ 5.33 (d, $J_{1,2}$ = 3.5 Hz, 0.4H, H-1_D α), 5.02 (d, $J_{1,2}$ = 1.5 Hz, 0.4H, H-1_C α), 4.98–4.96 (m, 1.2H, H-1_C β , H-1_D β), 4.18 (dd, $J_{2,3}$ = 10.4 Hz, 0.4H, H-2_D α), 4.11–3.78 (m, 7H, H-2_C, H-3_C, H-5_C, H-2_D β , $H-5_{D}\alpha$, $H-6a_{D}$, $H-6b_{D}$), 3.69–3.62 (m, 1H, $H-4_{D}$), 3.60–3.55 (m, 0.6H, H-5_D β), 3.50 (pt, J = 9.8 Hz, H-4_C), 1.31 (d, J_{5.6} = 6.3 Hz, 1.2H, H-6_C α), (d, $J_{5,6} = 6.3$ Hz, 1.8H, H-6_C β); ¹³C NMR (D₂O) δ 167.4 (NHCO β), 167.1 (NHCO α), 103.9 (C-1_Cβ), 103.7 (C-1_Cα), 96.5 $(C-1_{D}\beta)$, 94.3 $(CCl_{3}\beta)$, 94.1 $(CCl_{3}\alpha)$, 93.2 $(C-1_{D}\alpha)$, 83.6 $(C-3_{D}\beta)$, 81.5 (C- $3_{D}\alpha$), 78.8 (C- $5_{D}\beta$), 74.5 (C- 4_{C}), 74.4 (C- $5_{D}\alpha$), 73.3 (C- 2_{C}), 73.0 (C-3_C), 71.6 (C-5_C), 71.3 (C-4_D), 63.4 (C-6_D β), 63.3 (C-6_D α), 61.1 (C-2_D β), 58.4 (C-2_D α), 19.1 (C-6_C); HRMS (ESI⁺) m/z calcd for $C_{14}H_{22}Cl_3NO_{10}Na [M + Na]^+$ 492.0207, found 492.0186.

Computational Procedures. All calculations were performed using the hybrid density functional methods⁸⁷ integrated in the Gaussian 09 set of programs. The Lee, Yang, and Parr correlation functional method (B3LYP) was chosen.^{88,89} The 6-31G(3df,3pd) basis set was employed for each atom. Structural parameters and associated energies result from full geometry optimization in the gas phase, with no imposed constraints. The convergence criteria were set up so that the maximum atomic force is negligible.

Enzymatic Assays. Procedures were as described previously.⁵⁰

ASSOCIATED CONTENT

S Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b01407.

¹H and ¹³C NMR spectra for the target decasaccharide **5** and all novel compounds described in the Experimental Section (**3**, **6**–**9**, **11**–**22**, **24**–**26**, **36**, **37**, **40**, **45**, **47**–**56**); HPLC profile for decasaccharide **5**; tables of atom coordinates and absolute energies for compounds **25**–**27** (PDF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: laurence.mulard@pasteur.fr.

Present Address

[#]Oxeltis, Cap Gamma, 1682 rue de la Valsière, CS 27384, 34189 Montpellier, France.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank F. Bonhomme (CNRS UMR 3523) for HRMS recording. This work was supported by the French National Research Agency (Project GLUCODESIGN, ANR-08-PCVI-002-02) and the European Commission Seventh Framework Program (FP7/2007–2013) under Grant No. 261472-STOPENTERICS. This work was granted access to the HPC resources of CALMIP supercomputing center under the allocation P1101.

REFERENCES

- (1) Wang, C. C.; Lee, J. C.; Luo, S. Y.; Kulkarni, S. S.; Huang, Y. W.; Lee, C. C.; Chang, K. L.; Hung, S. C. *Nature* **2007**, 446, 896.
- (2) Zhu, X.; Schmidt, R. R. Angew. Chem., Int. Ed. 2009, 48, 1900.
- (3) Boltje, T. J.; Buskas, T.; Boons, G.-J. Nat. Chem. 2009, 1, 611.
- (4) Hsu, C.-H.; Hung, S.-C.; Wu, C.-Y.; Wong, C.-H. Angew. Chem., Int. Ed. **2011**, 50, 11872.
- (5) Lowary, T. L. Curr. Opin. Chem. Biol. 2013, 17, 990.
- (6) Ishiwata, A.; Ito, Y. J. Am. Chem. Soc. 2011, 133, 2275.
- (7) Calin, O.; Eller, S.; Seeberger, P. H. Angew. Chem., Int. Ed. 2013, 52, 5862.
- (8) Adibekian, A.; Stallforth, P.; Hecht, M.-L.; Werz, D. B.; Gagneux, P.; Seeberger, P. H. *Chem. Sci.* **2011**, *2*, 337.

(9) Palcic, M. M. Curr. Opin. Chem. Biol. 2011, 15, 226.

- (10) Armstrong, Z.; Withers, S. G. Biopolymers 2013, 99, 666.
- (11) Monsan, P.; Remaud-Siméon, M.; André, I. Curr. Opin. Microbiol. 2010, 13, 293.
- (12) Lennarz, W. J.; Lane, M. D.; Tolbert, T. J.; Wong, C. H. Encyclopedia of Biological Chemistry: Elsevier: New York, 2013; p 362.

(13) Filice, M.; Marciello, M. Curr. Org. Chem. **2013**, *17*, 701.

(14) Wang, Z.; Chinoy, Z. S.; Ambre, S. G.; Peng, W.; McBride, R.; de Vries, R. P.; Glushka, J.; Paulson, J. C.; Boons, G.-J. *Science* **2013**, *341*, 379.

- (15) Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S. Y.; AlMazroa, M. A.; Alvarado, M.; Anderson, H. R.; Anderson, L. M.; Andrews, K. G.; Atkinson, C.; Baddour, L. M.; Barker-Collo, S.; Bartels, D. H.; Bell, M. L.; Benjamin, E. J.; Bennett, D.; Bhalla, K.; Bikbov, B.; Abdulhak, A. B.; Birbeck, G.; Blyth, F.; Bolliger, I.; Boufous, S.; Bucello, C.; Burch, M.; Burney, P.; Carapetis, J.; Chen, H.; Chou, D.; Chugh, S. S.; Coffeng, L. E.; Colan, S. D.; Colquhoun, S.; Colson, K. E.; Condon, J.; Connor, M. D.; Cooper, L. T.; Corriere, M.; Cortinovis, M.; de Vaccaro, K. C.; Couser, W.; Cowie, B. C.; Criqui, M. H.; Cross, M.; Dabhadkar, K. C.; Dahodwala, N.; De Leo, D.; Degenhardt, L.; Delossantos, A.; Denenberg, J.; Des Jarlais, D. C.; Dharmaratne, S. D.; Dorsey, E. R.; Driscoll, T.; Duber, H.; Ebel, B.; Erwin, P. J.; Espindola, P.; Ezzati, M.; Feigin, V.; Flaxman, A. D.; Forouzanfar, M. H.; Fowkes, F. G. R.; Franklin, R.; Fransen, M.; Freeman, M. K.; Gabriel, S. E.; Gakidou, E.; Gaspari, F.; Gillum, R. F.; Gonzalez-Medina, D.; Halasa, Y. A.; Haring, D.; Harrison, J. E.; Havmoeller, R.; Hay, R. J.; Hoen, B.; Hotez, P. J.; Hoy, D.; Jacobsen, K. H.; James, S. L.; Jasrasaria, R.; Jayaraman, S.; Johns, N.; Karthikeyan, G.; Kassebaum, N.; Keren, A.; Khoo, J.-P.; Knowlton, L. M.; Kobusingye, O.; Koranteng, A.; Krishnamurthi, R.; Lipnick, M.; Lipshultz, S. E. Lancet 2012, 380, 2095.
- (16) von Seidlein, L.; Kim, D. R.; Ali, M.; Lee, H.; Wang, X.; Thiem, V. D.; Canh, D. G.; Chaicumpa, W.; Agtini, M. D.; Hossain, A.; Bhutta, Z. A.; Mason, C.; Sethabutr, O.; Talukder, K.; Nair, G. B.; Deen, J. L.; Kotloff, K.; Clemens, J. *PLoS Med.* **2006**, *3*, e353.
- (17) Klontz, K. C.; Singh, N. Expert Rev. Anti-Infect. Ther. 2015, 13, 69.
- (18) Robbins, J. B.; Kubler-Kielb, J.; Vinogradov, E.; Mocca, C.; Pozsgay, V.; Shiloach, J.; Schneerson, R. *Proc. Natl. Acad. Sci. U. S. A.* **2009**, *106*, 7974.
- (19) Pozsgay, V.; Chu, C.; Pannell, L.; Wolfe, J.; Robbins, J. B.; Schneerson, R. Proc. Natl. Acad. Sci. U. S. A. **1999**, *96*, 5194.
- (20) Pozsgay, V. Curr. Top. Med. Chem. 2008, 8, 126.

(21) Phalipon, A.; Tanguy, M.; Grandjean, C.; Guerreiro, C.; Belot, F.; Cohen, D.; Sansonetti, P. J.; Mulard, L. A. *J. Immunol.* **2009**, *182*, 2241.

(22) Phalipon, A.; Costachel, C.; Grandjean, C.; Thuizat, A.; Guerreiro, C.; Tanguy, M.; Nato, F.; Vulliez-Le Normand, B.; Belot, F.; Wright, K.; Marcel-Peyre, V.; Sansonetti, P. J.; Mulard, L. A. J. *Immunol.* **2006**, *176*, 1686.

(23) Perepelov, A. V.; Shekht, M. E.; Liu, B.; Shevelev, S. D.; Ledov, V. A.; Senchenkova, S. N.; L'vov, V. L.; Shashkov, A. S.; Feng, L.; Aparin, P. G.; Wang, L.; Knirel, Y. A. *FEMS Immunol. Med. Microbiol.* **2012**, *66*, 201.

(24) Sun, Q.; Knirel, Y. A.; Lan, R.; Wang, J.; Senchenkova, S. y. N.; Shashkov, A. S.; Wang, Y.; Wang, Y.; Luo, X.; Xu, J. *Glycobiology* **2014**, *24*, 305.

(25) Livio, S.; Strockbine, N. A.; Panchalingam, S.; Tennant, S. M.; Barry, E. M.; Marohn, M. E.; Antonio, M.; Hossain, A.; Mandomando, I.; Ochieng, J. B.; Oundo, J. O.; Qureshi, S.; Ramamurthy, T.; Tamboura, B.; Adegbola, R. A.; Hossain, M. J.; Saha, D.; Sen, S.; Faruque, A. S. G.; Alonso, P. L.; Breiman, R. F.; Zaidi, A. K. M.; Sur, D.; Sow, S. O.; Berkeley, L. Y.; O'Reilly, C. E.; Mintz, E. D.; Biswas, K.; Cohen, D.; Farag, T. H.; Nasrin, D.; Wu, Y.; Blackwelder, W. C.; Kotloff, K. L.; Nataro, J. P.; Levine, M. M. *Clin. Infect. Dis.* **2014**, *59*, 933.

(26) Wessel, H. P.; Bundle, D. R. J. Chem. Soc., Perkin Trans. 1 1985, 2251.

(27) Nifant'ev, N. E.; Shashkov, A. S.; Lipkind, G. M.; Kochetkov, N. K. *Carbohydr. Res.* **1992**, *237*, 95.

- (28) Segat-Dioury, F.; Mulard, L. A. Tetrahedron: Asymmetry 2002, 13, 2211.
- (29) Boutet, J.; Guerreiro, C.; Mulard, L. A. *Tetrahedron* 2008, 64, 10558.
- (30) Dhara, D.; Kar, R. K.; Bhunia, A.; Misra, A. K. Eur. J. Org. Chem. 2014, 2014, 4577.
- (31) Hargreaves, J.; Le Guen, Y.; Guerreiro, C.; Descroix, K.; Mulard, L. A. Org. Biomol. Chem. 2014, 12, 7728.
- (32) Komarova, B. S.; Orekhova, M. V.; Tsvetkov, Y. E.; Nifantiev, N. E. *Carbohydr. Res.* **2014**, *384*, 70.
- (33) de Kort, M.; Valentijn, A. R. P. M.; van der Marel, G. A.; van Boom, J. H. Tetrahedron Lett. **1997**, 38, 7629.
- (34) Crich, D.; Cai, W. L. J. Org. Chem. 1999, 64, 4926.
- (35) Pokorny, B.; Müller-Loennies, S.; Kosma, P. Carbohydr. Res. 2014, 391, 66.
- (36) Lemanski, G.; Ziegler, T. Eur. J. Org. Chem. 2006, 2006, 2618.

(37) Cumpstey, I. Carbohydr. Res. 2008, 343, 1553.

- (38) Iino, K.; Iwamoto, S.; Kasahara, Y.; Matsuda, K.; Tonozuka, T.; Nishikawa, A.; Ito, Y.; Matsuo, I. *Tetrahedron Lett.* **2012**, *53*, 4452.
- (39) Yasomanee, J. P.; Demchenko, A. V. Angew. Chem., Int. Ed. 2014, 53, 10453.
- (40) Kim, J.-H.; Yang, H.; Park, J.; Boons, G.-J. J. Am. Chem. Soc. 2005, 127, 12090.
- (41) Fascione, M. A.; Adshead, S. J.; Stalford, S. A.; Kilner, C. A.;
- Leach, A. G.; Turnbull, W. B. Chem. Commun. 2009, 5841.
- (42) Fang, T.; Mo, K.-F.; Boons, G.-J. J. Am. Chem. Soc. 2012, 134, 7545.
- (43) Fascione, M. A.; Kilner, C. A.; Leach, A. G.; Turnbull, W. B. Chem. Eur. J. 2012, 18, 321.
- (44) Allison, G. E.; Verma, N. K. Trends Microbiol. 2000, 8, 17.
- (45) See http://www.cazy.org.

(46) Daude, D.; Andre, I.; Monsan, P.; Remaud-Simeon, M. In *Carbohydrate Chemistry*; The Royal Society of Chemistry: London, 2014; Vol. 40, p 624.

(47) Champion, E.; André, I.; Moulis, C.; Boutet, J.; Descroix, K.; Morel, S.; Monsan, P.; Mulard, L. A.; Remaud-Siméon, M. J. Am. Chem. Soc. 2009, 131, 7379.

(48) Champion, E.; Guerin, F.; Moulis, C.; Barbe, S.; Thu Hoai, T.; Morel, S.; Descroix, K.; Monsan, P.; Mourey, L.; Mulard, L. A.; Tranier, S.; Remaud-Siméon, M.; André, I. *J. Am. Chem. Soc.* **2012**, *134*, 18677.

(49) Urbach, C.; Halila, S.; Guerreiro, C.; Driguez, H.; Mulard, L. A.; Armand, S. *ChemBioChem* **2014**, *15*, 293.

- (50) Salamone, S.; Guerreiro, C.; Cambon, E.; Andre, I.; Remaud-Simeon, M.; Mulard, L. A. Chem. Commun. 2015, 51, 2581.
- (51) Bélot, F.; Guerreiro, C.; Baleux, F.; Mulard, L. A. Chem. Eur. J. 2005, 11, 1625.
- (52) Evans, M. E.; Parrish, F. W. Carbohydr. Res. 1977, 54, 105.
- (53) Clode, D. M. Chem. Rev. 1979, 79, 491.
- (54) Chung, S.-K.; Moon, S.-H. J. Chem. Soc., Chem. Commun. 1992, 77.
- (55) Mulard, L. A.; Costachel, C.; Sansonetti, P. J. J. Carbohydr. Chem. 2000, 19, 849.
- (56) Debost, J.-L.; Gelas, J.; Horton, D.; Mols, O. Carbohydr. Res. 1984, 125, 329.
- (57) Hanessian, S.; Delorme, D.; Tyler, P. C.; Demailly, G.; Chapleur, Y. Can. J. Chem. **1983**, 61, 634.
- (58) Catelani, G.; D'Andrea, F.; Puccioni, L. *Carbohydr. Res.* 2000, 324, 204.
- (59) Yadav, J. S.; Satyanarayana, M.; Raghavendra, S.; Balanarsaiah, E. *Tetrahedron Lett.* **2005**, *46*, 8745.
- (60) Yadav, J. S.; Raghavendra, S.; Satyanarayana, M.; Balanarsaiah, E. Synlett **2005**, 2461.
- (61) Danieli, B.; Luisetti, M.; Sampognaro, G.; Carrea, G.; Riva, S. J. Mol. Catal. B: Enzym. **1997**, *3*, 193.
- (62) Rencurosi, A.; Poletti, L.; Guerrini, M.; Russo, G.; Lay, L. Carbohydr. Res. 2002, 337, 473.
- (63) Plou, F. J.; Cruces, M. A.; Ferrer, M.; Fuentes, G.; Pastor, E.; Bernabé, M.; Christensen, M.; Comelles, F.; Parra, J. L.; Ballesteros, A. J. Biotechnol. **2002**, *96*, 55.
- (64) Sherman, A. A.; Yudina, O. N.; Mironov, Y. V.; Sukhova, E. V.; Shashkov, A. S.; Menshov, V. M.; Nifantiev, N. E. *Carbohydr. Res.* **2001**, 336, 13.
- (65) Pinto, B. M.; Reimer, K. B.; Morissette, D. G.; Bundle, D. R. J. Org. Chem. 1989, 54, 2650.
- (66) Pinto, B. M.; Reimer, K. B.; Morissette, D. G.; Bundle, D. R. J. Chem. Soc., Perkin Trans. 1 1990, 293.
- (67) Bélot, F.; Wright, K.; Costachel, C.; Phalipon, A.; Mulard, L. A. J. Org. Chem. **2004**, 69, 1060.
- (68) Oltvoort, J. J.; Van Boeckel, C. A. A.; De Koning, J. H.; Van Boom, J. H. Synthesis **1981**, *3*, 305.
- (69) Nashed, M. A.; Anderson, L. J. Chem. Soc., Chem. Commun. 1982, 1274.
- (70) Boutet, J.; Guerreiro, C.; Mulard, L. A. J. Org. Chem. 2009, 74, 2651.
- (71) Boutet, J.; Mulard, L. A. Eur. J. Org. Chem. 2008, 2008, 5526.
- (72) Chassagne, P.; Fontana, C.; Guerreiro, C.; Gauthier, C.; Phalipon, A.; Widmalm, G.; Mulard, L. A. *Eur. J. Org. Chem.* **2013**, 2013, 4085.
- (73) Mulard, L. A.; Clement, M. J.; Segat-Dioury, F.; Delepierre, M. Tetrahedron 2002, 58, 2593.
- (74) Palomino, J. C. C.; Rensoli, M. H.; Bencomo, V. V. J. Carbohydr. Chem. **1996**, 15, 137.
- (75) Mulard, L. A.; Guerreiro, C. Tetrahedron 2004, 60, 2475.
- (76) Lucas, R.; Hamza, D.; Lubineau, A.; Bonnaffe, D. Eur. J. Org. Chem. 2004, 2004, 2107.
- (77) André, I.; Mazeau, K.; Taravel, F. R.; Tvaroska, I. Int. J. Biol. Macromol. 1995, 17, 189.
- (78) Muller, N.; Reiter, R. C. J. Chem. Phys. 1965, 42, 3265.
- (79) van Steijn, A. M. P.; Kamerling, J. P.; Vliegenthart, J. F. G. Carbohydr. Res. 1991, 211, 261.
- (80) Gurjar, M. K.; Mainkar, A. S. Tetrahedron 1992, 48, 6729.
- (81) Du, Y.; Kong, F. J. Carbohydr. Chem. 1999, 18, 655.
- (82) Potocki De Montalk, G.; Remaud-Siméon, M.; Willemot, R. M.; Planchot, V.; Monsan, P. J. Bacteriol. **1999**, *181*, 375.
- (83) Salamone, S.; Boisbrun, M.; Didierjean, C.; Chapleur, Y. Carbohydr. Res. 2014, 386, 99.
- (84) Jütten, P.; Scharf, H.-D. Carbohydr. Res. 1991, 212, 93.
- (85) Pirrung, M. C.; Shuey, S. W.; Lever, D. C.; Fallon, L. Bioorg. Med. Chem. Lett. **1994**, *4*, 1345.

(86) Verges, A.; Cambon, E.; Barbe, S.; Salamone, S.; Le Guen, Y.; Moulis, C.; Mulard, L. A.; Remaud-Siméon, M.; André, I. *ACS Catal.* **2015**, *5*, 1186.

(87) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, N. J.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian, Inc.: Wallingford, CT, 2009.

(88) Becke, A. D. Phys. Rev. A: At., Mol., Opt. Phys. 1988, 38, 3098.
(89) Lee, C.; Yang, W.; Parr, R. G. Phys. Rev. B: Condens. Matter Mater. Phys. 1988, 37, 785.